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Abstract
This study identifies the proportion o f anger problems referred to East Glasgow’s Clinical 
Psychology Department. It examines whether the number o f anger referrals differs between 
sectors, referring agent and the client’s clinical characteristics. The implications for clinical 
practice are discussed.
(40 word summary in accordance with Clinical Psychology guidelines)
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Introduction
Anger is a powerful normal emotion that is common in everyday life. However, anger is 
often viewed as a negative construct. The definition of anger and what constitutes 
problematic anger is debated in clinical and research settings. Researchers have put forward 
different explanations of anger. Ray Novaco proposed that anger is a cognitively mediated 
emotional state that may have positive functions e.g. release bodily tension. However, he also 
argues that it has to be controlled for healthy functioning. Novaco believes anger becomes a 
clinical problem when it is ‘dysregulated’ -  that is when it’s activation, expression and 
experience occur without appropriate controls (Ramm and Novaco, 2002).
Dysregulated anger interferes with efficient thinking, impairs physiological health and can 
result in aggressive behaviour towards the self or others (Kay et al. 1988). As well as being a 
problem in itself, anger is a common feature of other psychiatric problems such as personality 
disorders (Blackburn 1993), schizophrenia (Levy and Howells 1991) and mood disorders, as 
well as reactions to trauma such as post-traumatic stress disorder (PTSD) (Chemtob et al. 
1997). Clients with anger problems can therefore be expected to make up a standard 
component of adult clinical psychology practice.
Working with patients who are experiencing anger problems can provide a particular clinical 
challenge. For example, there is considerable evidence to suggest that anger is a mediator in 
violent offences in the community and in clinical settings such as psychiatric wards (Levy and 
Howells 1991). Clients with anger problems may therefore present a danger to staff 
(Cunningham et al. 2003). Anger problems may also be a long-standing strategy to cope with 
recurrent adversity (Novaco 1997). The patient may have found this strategy to be, in some 
ways, a successful way of dealing with life’s difficulties, resulting in an ingrained pattern of
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behaviour. Patients with anger problems therefore have a reputation of being resistant to 
treatment (Howells 1998), and may be met with therapeutic pessimism on the part of the 
therapist (Renwick et al. 1997). Given the difficulties outlined above, there has been growing 
concern amongst clinicians about how best to manage patients who present with anger 
problems to clinical psychology departments.
Anger is associated with different aetiological factors and presents along a spectrum of 
severity. It is therefore helpful to apply criteria to differentiate anger problems when working 
in clinical settings. It has been suggested that anger problems can be differentiated by the 
extent to which the client expresses anger towards other people or the environment (anger 
out), and the extent to which they suppress angry feelings (anger in) (Speilberger, 1983). 
Determining the client’s ability to control anger is another useful way of understanding the 
differences in anger problems. The State Trait Anger Expression Inventory (Speilberger, 
1979) measures anger expression according to the extent to which it is expressed, suppressed 
and controlled. Adult mental health psychology departments may be better equipped to deal 
with clients with anger problems who are more in control of their anger, and thus less likely to 
direct their anger towards others and the environment.
Clients who were experiencing high expressed anger and poor anger control were, until 
recently, referred to the forensic team in Glasgow. The forensic team provided a specialist 
service for people with anger problems called the ‘Anger Management Fast Track’ service 
(AMFT). However, the number of referrals was found to be unmanageable by the AMFT 
team and the team also felt that many of the referrals were inappropriate, as not all referrals 
were forensic in nature (Munro 2002). The service was therefore closed in June 2002.
Whilst it could be argued that the complex needs of patients with anger problems may be best
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met by a specialist service, there nonetheless remains the task of identifying how best to 
manage anger referrals within the more generic adult mental health setting. The East Glasgow 
adult psychology team believed that they were experiencing a high volume of referrals of 
patients with anger problems. They were also concerned about the clinical characteristics of 
people being referred with anger problems. Staff were particularly concerned that the client 
may have anger that was directed towards others in the environment (anger out) or a forensic 
history, as such characteristics are associated with greater risk to others.
This project sought to audit the number of patients with anger problems being referred to the 
psychology department in East Glasgow in order to identify the size of the service need for 
these patients. Methods of managing the service need could then be developed. This study 
audits the number of referrals of patients with anger problems relative to other problems. It 
also identifies whether there are any significant differences in the number of referrals made by 
General Practitioners (GPs), compared to Community Mental Health Teams (CMHTs), and 
across the East’s 3 sub sectors: City (comprising City Centre, Denniston, Parkhead and 
Bridgeton), Mid (comprising Riddrie, Camtyne, Shettleston and Carmyle) and Easterhouse 
(comprising Ballieston, Garthamlock, Easterhouse, Barlanark). The clinical characteristics of 
the patients with anger problems are also explored.
Aims
The study therefore aimed to address the following exploratory objectives:
1. Describe the relative proportions of problem type referred to the department during 
the period 1.04.03-31.03.04.
2. Identify if there was a significant difference between the number of referrals of
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patients with anger problems across the City, Mid and Easterhouse sectors.
3. Identify if there was a significant difference between GPs and CMHTs in the 
number of referrals made for patients with anger problems.
4. Describe the clinical characteristics of clients referred with anger problems i.e. 
express ‘anger out’, compared with ‘anger in’, gender, comorbid problems and 
forensic history.
Method
Procedure
a) Information was accessed from the letters referring clients to adult psychology 
services by GPs and CMHTs in East Glasgow between 01.04.03 and 31.03.04. Four hundred 
and seventy five referrals were reviewed out of 560 referrals (85% of the referral population).
b) Demographic information such as age, gender, postcode, presenting problems and any 
mention of forensic history was extracted from referral letters. Presenting problems were 
categorised according to EPPIC criteria (Urquart 1997). This is a method of categorising 
presenting problems that was designed in the West Coast of Scotland and validated in 
community and clinical samples. Up to three categories of problem were recorded for each 
referral.
c) An anger problem was recorded whenever there was any mention of a loss of control 
of anger, including descriptions of irritability, loss of temper, aggressive or violent behaviour
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such as assaulting others, or an indication that anger was affecting relationships. Anger was 
classified as ‘out’ when the anger was described as being expressed towards individuals or the 
environment. Anger was described as ‘in’ if the anger was described as being suppressed, or 
not affecting others or the environment. If both were mentioned, then the problem was 
categorised as ‘anger out’.
d) Data were analysed using descriptive statistics, with Chi-Square tests being employed 
to examine associations between unrelated categorical data.
Results
The referral population for the year 1.04.03 to 31.03.04 was 560 individuals and the following 
analyses are based on 475 cases (85%).
1. Relative proportions of problem type referred to the department
The department received referrals for a wide range of problem types during the period 
assessed (Figure 1). The most frequent referral was for depression (33%). Problems related 
to anxiety (including GAD, panic, social phobia, agoraphobia, OCD) were the next most 
common referral (31%), then PTSD (13%), anger (8%), sexual abuse (6%), insomnia (3%) 
and eating disorders (2%). Additional problems collapsed into ‘other’ category (4%) included 
psychosis, intellectual/memory impairment, substance abuse and personality disorder.
Insert figure 1 here
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Anger referrals were therefore less common than depression, anxiety and PTSD but more 
common than eating disorders, sleep problems and psychosis. It is therefore one of the more 
common referrals totalling 37 out of 475 (8%) referrals.
2. Frequency of anger referrals by sector
The frequencies of anger referrals by sector within the East Psychology Division are 
illustrated in Table 1. The frequency of anger referrals was highest in the Mid-Sector (9.6%) 
and Easterhouse sectors (8.4%). Anger referrals were less frequent in the City (5.9%). 
However, Chi-square analysis did not confirm the difference in anger referrals between 
sectors as significant (%2 = 1.52, df = 2, p>.05).
Insert table 1 here
3. Frequency of Anger referrals by referrer
Table 1 also illustrates the frequency of anger referrals by referrer. GPs referred people with 
anger problems more frequently than CMHTs across all sectors. The CMHT in the Mid­
sector referred people with anger problems more frequently than in the City or Easterhouse 
sectors. Chi-square analyses of data revealed no significant difference overall between GPs 
and CMHTs in the frequency of anger referrals compared to non-anger referrals (%2 = 0.53, df 
= 1, p>.05), and no significant difference when the City and Mid-sectors were analysed 
individually i.e. City-sector (%2 = 0.01, df = 1, >.05), Mid-sector (%2 = 0.35, df = 1, p>0.05). 
However, GPs referred people with anger problems significantly more frequently than the 
CMHT in the Easterhouse sector (%2 = 6.61, df = 1, p<.002).
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4. Clinical characteristics of clients referred with anger problems i.e. gender, comorbid
problems, anger in/out and forensic history 
Gender
Overall, more females were referred to the department than males (57% female referrals). 
However, the opposite pattern was shown in the anger referrals with males making up 73% of 
the anger referrals. This difference was significant = 13.18, df = 1, p<.001).
Comorbid Problems
Fifty four percent of people referred with anger problems were also experiencing other mental 
health problems. The level of comorbidity was similar between sectors (City = 63.6%, Mid = 
61.5%. Easterhouse = 53.8%). Problems associated with anger referrals include
alcohol/substance abuse (N=6), depression (N=6), anxiety (N=6), PTSD (N=2), 
relationship/marital problems (N=2), learning disability (N=l) and psychosis (N=l).
Anger In/Out
Ninety one percent of referrals of people with anger problems describe anger that is expressed 
towards individuals or the environment, rather than suppressed. Therefore the vast majority 
of referrals were in the ‘anger out’ category. This information is based on 34 out of the 37 
referrals. Comments describing expressed anger problems include: ‘violent outbursts’, ‘loses 
temper with family’ and ‘destroys property’. This level was similar across all sectors.
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Forensic History
Twenty four percent of people referred with anger problems had a forensic history mentioned 
in the referral letter. This information is based on 34 out of 37 referrals. This comprised 2 
referrals to the City, 3 referrals to the Mid and 3 referrals to the Easterhouse sectors.
Requesting Anger management
It was also noted which referrals of people with anger problems were specifically requesting 
Anger Management (AM) services. This information is also based on 34 out of 37 referrals. 
68% of referrals specifically requested AM. This frequency of requests for AM was higher in 
the Easterhouse sector (83%) than in the Mid (58%) or City sectors (60%).
Discussion
Service Need
This study has determined the service need for patients with anger problems in adult 
psychology in East Glasgow. Anger problems make up 8% of total referrals, which is less 
than anxiety, depression and PTSD, but more common than other mental health problems 
such as eating disorders, sleep disorders, psychosis and intellectual impairment. Clients 
experiencing anger constitute a considerable component of patients seen in clinical practice, 
and this has implications for psychologists working in East Glasgow. The Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV, APA, 1994) lacks a specific anger 
diagnosis. Problems with a DSM classification are more easily diagnosed and measurable 
than unclassified problems. This may partly explain why there is only a small literature on 
managing anger problems in clinical practice. Psychologists are therefore likely to be more 
familiar with treatment approaches for problems that have a DSM diagnosis, such as eating 
disorders, than anger problems. Psychologists in East Glasgow can now be made aware that
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they are actually very likely to encounter patients with anger problems and therefore acquaint 
themselves with approaches to dealing with anger e.g. through continuing professional 
development (CPD) workshops.
Treatment Implications
Now that a service need has been identified, the question arises regarding how best to manage 
the clients with anger problems referred to the department. The department could continue to 
treat anger problems on an individual basis. However, there is increasing evidence that group 
approaches can be employed to address problematic anger in adult psychology departments 
(Mayne & Ambrose 1999, O’Loughlin et al. 2004). These groups are either based on a 
Cognitive Behavioural Therapy (CBT) (Siddle et al. 2003), or on a psycho-educational 
approach akin to White’s Anxiety and Stress Groups (White, 2000). An anger management 
group would be an evidence-based approach to managing the service need. Alternatively, 
some clients with anger problems may be suitable for the Stress Management Group that is 
currently run within the department.
One noteworthy caution in planning services for patients with anger problems is the 
considerable non-attendance rate. Siddle et al. (2003) reported that 41% of patients referred 
with anger problems did not attend their first appointment and only 9% of those referred 
attended for the whole course of CBT. In effect, it is likely that the actual service need for 
these patients is less than indicated by the number of referrals.
Clinical Characteristics
The clinical characteristics of patients referred with anger problems also have implications for 
practice. Patients are significantly more likely to be male, typically present with comorbid 
problems, such as alcohol abuse, and are also likely to express their anger towards others
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(anger out). One quarter of those referred with anger problems also had a forensic history. 
They therefore fit with the clinical challenges associated with anger problems described in the 
literature (Kay et al. 1988, O’Loughlin et al. 2004), and with the characteristics of patients 
that are typically met with therapeutic pessimism (Renwick et al. 1997). They also fit with 
the concerns held by members of staff in the department, which were that the client may have 
anger that was directed towards others in the environment and that the client may have a 
forensic history.
Methods of addressing staff concerns should therefore be considered. A teaching session 
from a forensic clinical psychologist could be arranged at a team meeting, and team meetings 
could also refresh team members on general safety procedures. It may also be worth 
considering training interested members of the department in risk assessment, or considering 
joint assessments when seeing a client referred with expressed anger problems.
Referral Patterns
Anger referrals were more frequent in the Easterhouse and Mid-sectors than the City-sector 
and this fits with the experience of clinicians in the department. Almost two thirds of referrals 
of people experiencing anger problems specifically requested Anger Management (AM). The 
closure of the Douglas Inch AMFT service means that referrals for AM have to be dealt with 
within the East Psychology Department and the lead clinicians must decide whether they can 
provide an AM service. This is especially important in the Easterhouse sector, which 
received the highest percentage of people referred specifically for Anger Management.
Overall, GPs referred people with anger problems more than CMHTs. There was a smaller 
difference in the frequency of GP and CMHT referrals in the Mid-sector. It may be that 
psychology involvement in the CMHTs in the City and Easterhouse sectors has resulted in
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greater awareness of the type of services provided by the psychology department, whereas 
there has been less involvement from psychology in the Mid-sector CMHT, as there had been 
an unfilled post in there for some time.
There are a number of ways the department could utilise the information gathered by this 
study to influence referral patterns. More information could be provided to GPs in the area 
with regards to the types of intervention offered to clients with anger problems and what 
constitutes an appropriate referral. This may be particularly appropriate in the Easterhouse 
sector where the number of referrals from GPs of people with anger referrals was particularly 
high. Additionally, the newly appointed psychologist in the Mid-sector could address any 
queries held by the CMHT as to what constitutes an appropriate anger referral and what type 
of intervention may be appropriate.
Limitations
One of the limitations of this study was that problems were classified using referral letters. 
There are some disadvantages associated with using referral letters. Using referral letters 
means that the number of people with anger problems calculated in this study is an estimation 
that may either under-reflect or overestimate problematic anger, e.g. patients may not view 
their anger as problematic and therefore not mention it to their GP, or, GPs may view anger 
management as an appropriate way to view a clients difficulties where the underlying problem 
may be relationship difficulties. Similarly, the number of people being referred with a 
forensic history is also an estimate.
Other limitations include the sampling of referrals i.e. only 85% of those referred to 
psychology were reviewed in this study. The remaining referrals were either temporarily 
unavailable or already assigned to treatment. It is important to note that referrals assigned to
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early treatment may have differed from the remaining population in terms of urgency but it is 
not thought that this has impacted on the estimation of anger referrals.
The study’s findings have limited generalisability. It is specifically designed to assess the 
needs of the psychology department in East Glasgow. However, it does raise issues that are 
relevant to other psychology departments in Glasgow as the closure of the Douglas Inch 
Anger Management Fast-Track system means that all psychology departments in Glasgow 
have more responsibility for managing anger referrals.
Action Points
The results of the study were shared with the team at a departmental meeting. Appendix 1.2 
contains details of the action plan. Possible interventions suggested by the findings of the 
study include:
• Staff teaching on managing clients with anger problems and conducting risk
assessment.
• Developing an anger management group.
• Screening clients with anger problems for the Stress Management Groups.
• Liasing with referrers to improve knowledge of the services provided and what
information to include in referral letters.
Future Research
A future study could audit the number of clients with anger problems actually being seen in 
clinical practice by gathering information from clinicians. The success of the interventions 
suggested by this study, such as the Anger Management group, should be audited at a future 
date.
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Conclusions
This study has identified that the department of clinical psychology in the east of Glasgow 
receives a considerable number of referrals of people with anger problems. It has also 
identified the clinical characteristics and referral patterns of patients. A number of 
suggestions arise from this study including basing more closely with referrers and developing 
new ways of managing patients with anger problems.
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Table 1 Frequency and percentage o f  anger referrals by sector and referrer
City Mid Easterhouse
Number Percentage Number Percentage Number Percentage
Total 11 (184)1 5.9 13 (136) 9.6 13 (155) 8.4
GP 9 (118) 7.6 9 (91) 9.9 12(91) 13.2
CMHT 2 (66) 3.0 4 (45) 8.9 1 (64) 1.6
Numbers in parentheses indicate total sample.
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ABSTRACT
Objectives: This paper reviews the psychometric properties of the BMQ, with a particular 
focus on the strength of the relationship between BMQ scales and adherence to medicines in 
chronic illness populations.
Data Sources: Electronic searches of the databases: CDSR, MEDLINE, PsychlNFO,
EMBASE, CINAHL and Google Scholar were conducted. Hand searches were also 
conducted on three key journals and reference lists of related articles.
Study Selection and Data Extraction: Studies were included when participants were reported 
as suffering from a chronic illness, were taking medication for that illness and were adults. 
Studies were published in a peer-reviewed journal, adopted the Beliefs about Medicines 
Questionnaire to measure treatment beliefs and employed a measure of adherence. 
Information on reliability, validity and relationship to adherence in bivariate and multivariate 
analyses were extracted. Methodological issues that may impact on findings were also 
extracted.
Results: Seventeen studies were included in this review. Studies were too heterogeneous to 
warrant meta-analysis. The Necessity Scale was significant in 71% of bivariate analyses, had 
the largest effect sizes and remained a significant predictor in all but one of the multivariate 
analyses it was entered into. The Concerns Scale was significant in fewer bivariate analyses 
(58%), had smaller effect sizes and remained significant in fewer regression analyses (43%). 
The general scales were less strongly associated with adherence in bivariate and multivariate 
analyses than the specific scales.
Conclusions: Specific scales in the BMQ were found to be associated with adherence in 
theoretically valid and reliable ways. The Necessity Scale was more strongly related to 
adherence than the Concerns Scale although there were differences between illness 
populations. The BMQ general scales were less strongly associated with adherence but have 
been adopted in fewer studies so limited conclusions regarding their association with 
adherence can be drawn. The results suggest that peoples’ beliefs about medicines are related 
to adherence. Research now needs to focus on investigating if adherence can be improved by 
interventions designed to restructure beliefs about medicines.
Key phrases: Beliefs about medicines questionnaire, medicine beliefs, self-regulatory model, 
adherence
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INTRODUCTION
The role of beliefs about medicines in adherence
The prescription of medication is one of the most common forms of modem treatment yet 
average adherence rates to these medicines have been estimated at a modest 50% (Sackett & 
Snow, 1979; Millar, 1997), substantially reducing treatment effectiveness (Rogers & 
Bullman, 1995). Despite this finding, health professionals and pharmaceutical companies 
have tended to focus on improving the range of medicines available, and efforts to improve 
adherence have been largely neglected (Shaw, 2003). As the number of effective self­
administered treatments increase, the need for a better understanding and management of the 
factors determining adherence intensifies.
There is no consensus on the factors that best predict adherence. However, the literature 
currently advocates differentiating between intentional and involuntary non-adherence. 
Involuntary non-adherence concerns patients failing to follow recommendations because they 
forget to take them or they do not understand instructions. Intentional non-adherence relates 
to patients deciding not to take medication as prescribed, in other words, the patient’s 
adherence behaviour is governed by a rational decision (Weintraub, 1990).
Interventions to improve adherence have focused on both non-intentional and, to a lesser 
extent, intentional adherence (Haynes, McKibbon & Kanani, 1996; McDonald, Garg, & 
Haynes, 2002). Interventions have ranged from very simple i.e. changing dosing schedule, to 
complex combinations of techniques (e.g. counselling, patient leaflets, telephone follow up 
and support group, Bailey, Richards & Brooks, 1990). A recent review concludes that there is 
little evidence that conventional interventions are effective, or even cost effective, and calls 
for innovative approaches to improving adherence (McDonald et al. 2002). Few of the 
studies included in the review expressly focus on intentional non-adherence. None focused
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specifically on patients’ beliefs about their medicines or illness, although they did provide 
education on illness and medicines, which may have indirectly altered beliefs.
Shaw (2003) proposes that it is patient’s beliefs that govern their adherence behaviour and the 
present challenge for health professionals is to create an environment that respects patients’ 
personal decisions as well as professional expertise. This opinion has been substantiated by a 
burgeoning literature on patients’ beliefs about illness and treatment. The self-regulatory 
model (Leventhal, Deifenbach & Leventhal, 1992) is one of a number of models developed in 
the health psychology literature to explain how psychological factors influence adherence 
behaviour. The self-regulatory model proposes that the patient’s perceptions of their illness 
affect the way they take their medication. Patients’ illness perceptions have been 
operationalised in the ‘Illness Perceptions Questionnaire’ (Weinman, Petrie, Moss-Morris & 
Home, 1996) and have been successfully used to assess illness perceptions in a range of 
illnesses. Hagger and Orbell (2003) recently reviewed the evidence and concluded that illness 
perceptions are indeed related to adherence.
In recent years it has been suggested that including a measure of patients’ medication beliefs 
could increase the value of the self-regulatory model in explaining adherence behaviour. The 
literature had historically suggested that medication beliefs were also related to adherence 
(see Home, 1997 for a review) but there could not be comparisons made between studies, as 
these beliefs had not been measured in any standardised way. Home, Weinman and Hankins 
(1999) published the ‘Beliefs about Medicines Questionnaire’ (BMQ) to provide a 
standardised way of measuring treatment beliefs. There have since been a substantial number 
of authors adopting the BMQ to measure beliefs about medicine in a regimented manner.
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Description of the BMP
Home et al. (1999) published data on the psychometric properties of the BMQ and it has been 
used in over 20 studies since. It is an 18-item questionnaire designed to assess the views a 
person has about their medicines (see Appendix 2.2 for full measure). The questionnaire 
includes 2 sections:
1) The ‘specific’ section contains two 5-item scales measuring the concerns one has with 
specific medication and the perceived necessity of medicines prescribed for a 
particular condition. An example from the necessity scale is: “My health, at present, 
depends on my medications”. An example from the concerns scale is: “I sometimes 
worry about the long-term effects of my medicines”.
2) The ‘general’ section measures general views about medicines as a whole. It contains 
two 4-item scales measuring beliefs about the harms associated with medications and 
beliefs that doctors overuse medicines. An example from the harms scale is: 
“Medicines do more harm than good”. An example from the overuse scale is: 
“Doctors use too many medicines”.
Some studies have combined the BMQ specific scales or general scales into a differential. 
This is interesting as it relates to models of health behaviour proposing that people weigh up 
the costs and benefits of health behaviours. For example, patients may consider their beliefs 
regarding the necessity of their medication in relation to their concerns before deciding 
whether or not to take the medication.
25
Application of the BMQ
The BMQ was originally validated on a population of people taking medicines for different 
health conditions (asthma, renal, cardiac, general medical, diabetes and psychiatric) and 
compared with people seeking allopathic and complementary treatments. It has since been 
used on a wider population range including other clinical populations such as HIV and renal 
transplant patients (e.g. Gellaitry, Cooper, Davies, Fisher, Leake & Home, 2005; Butler, 
Peveler, Roderick, Smith, Home & Mason, 2004) acute conditions (e.g. Bekker, Gough, & 
Williams, 2003; Lam, Stevenson, Britten & Leventhal, 2001) and healthy students (e.g. 
Home, Frost, Hankins & Wright, 2001; Home, Graupner, Frost, Weinman, Wright & 
Hankins, 2004).
Although the BMQ is being applied in a wider range of populations, Home et al. (1999) 
suggest that beliefs may differ between chronic and acute illness conditions, for example, 
beliefs about the necessity of medicines are stronger in chronic illness populations than in 
populations suffering form more acute conditions. Therefore, in order to increase 
homogeneity and improve comparability of findings between studies it was decided that this 
review should focus on chronic illness populations only.
Importance of predictive validity
Criterion validity has the closest relationship to what is intuitively believed to be validity. 
Nunnally (1967) has described criterion validity as “at issue when the purpose is to use an 
instmment to estimate some important form of behaviour that is external to the instmment 
itself, the latter being referred to as the criterion”. Therefore, one of the most important 
questions to assess in reviewing the psychometric properties of a measure is the relationship 
between the measure and the criterion. In this case the criterion is how the BMQ relates to 
adherence behaviour.
26
The growing number of studies using the BMQ to measure adherence means it is difficult to 
assess the available evidence. Systematic reviews can helpfully synthesise the evidence and 
provide clear and unbiased overviews (Dickson & Entwistle, 1996). This is the first review to 
focus on how the BMQ scales relate to adherence.
Inclusion/Exclusion Criteria
Studies were included if:
1) Full study details were published in a peer-reviewed journal.
2) Participants were suffering from a chronic illness and were taking medication for that 
illness. In this review chronic illness was defined as an illness lasting more than three 
months in line with common medical practice.
3) Beliefs about medicines were measured using the BMQ.
4) Adherence was measured by self-report or objective measures.
5) The relationship between the BMQ and measures of adherence were reported.
6) Participants were over 18 years of age. This criterion was adopted as younger 
individuals may have assistance with adherence to medicines and this could affect the 
relationship between medication beliefs and adherence.
Studies were excluded if:
1) The BMQ was altered and the study authors did not report at least minimal 
psychometric data on the altered measure.
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Review Objectives
This paper will review the psychometric properties of the BMQ, with a particular focus on the 
strength of the relationship between BMQ scales and adherence to medicines in chronic 
illness samples.
METHODS 
Search Strategy
1) An electronic search was conducted of the following electronic databases for the period 
1999 (date of publication of the BMQ) to October 2005: CDSR, DARE, CCT, CINAHL, 
EMBASE, MEDLINE, PsychlNFO and Google Scholar.
2) Key search terms included: [BMQ] or [beliefS about medicineS] or [beliefs about 
medication] or [medication representations] or [medicines and beliefs] or [self-regulatory 
model] or [common sense model] or [illness perceptions] or [illness perceptions 
questionnaire].
3) Papers published by the original BMQ authors were also reviewed (Home R, Weinman J 
and Hankins M).
4) Hand searches on the following relevant journals were also conducted for the same time 
period: British Journal of Health Psychology, Psychology and Health, Psychology, Health and 
Medicine.
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5) Reference lists of included papers were also scanned for suitable papers.
6) Conference presentation abstracts were not included, as the full papers had not been 
subjected to the peer review process (Sharpe, 1997), which would have provided some 
reassurance regarding minimal levels of study quality. Time constraints made it difficult to 
guarantee locating unpublished data sets and these were also excluded. This review therefore 
focuses on published literature. However, it is acknowledged that reviewing published data 
only may introduce biases in the review conclusions. These potential issues are addressed 
later.
Computerised Search
The initial search identified 1062 potential papers for inclusion in the review. This was 
reduced to 714 once limited to English and humans then duplicates removed. Based on title 
and abstract alone, 679 were excluded. This left 35 papers that were reviewed in more detail. 
Agreement was reached between the reviewer and an independent rater (also undertaking 
doctorate level training) on studies that fulfilled the above inclusion criteria (see Figure 1 for 
details of the exclusion procedure). As a result of this process 17 studies were retained for 
inclusion in this review.
Insert Figure 1 here
Other search procedures
Other search procedures adopted did not result in any additional papers that matched the 
inclusion criteria indicating that the search criteria used were comprehensive.
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Evaluation of Study Quality
There is debate regarding which critical appraisal tools are most appropriate for which 
research design. A recent review of critical appraisal tools (Katrak, Bialocerowski, Massy- 
Westropp, Kumar & Gimmer, 2004) concluded that there is no ‘gold standard’ critical 
appraisal tool for any type of research, and there are few specific guidelines for cross- 
sectional observation studies such as those included in this review. Studies were therefore 
evaluated using criteria adapted from the Scottish Intercollegiate Guidelines Network (SIGN) 
‘Guideline Developers’ Handbook’ (Scottish Intercollegiate Guidelines Network, 2004).
Additionally, because of the design of these studies, there are few criteria that automatically 
preclude the study from being used as evidence. The criteria were used to determine the level 
of confidence in the findings of the study. The studies were rated according to 24 facets of 
design quality and possible scores ranged between 0 and 26. Papers were then ranked 
according to their percentage score and assigned to one of four quality categories (see 
Appendix 2.3).
An independent rater (as above) evaluated half of the studies. 100% agreement was reached 
between reviewer and the independent rater following discussion. The majority of included 
studies were rated A (65%). No studies were rated D (The findings of the study are thought 
likely or very likely to be affected by study quality).
Data Extraction
The following data were extracted from included studies:
1) The reliability and validity of the BMQ.
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2) The bivariate correlation between the BMQ scales and adherence to medicines.
3) Variables inputted into regression analyses and significant findings.
4) Methodological issues that may limit generalisability of findings.
RESULTS
Results begin by giving an overview of the characteristics of included studies. Findings 
regarding the reliability and validity of the measure and the relationship between BMQ scales 
and adherence are then presented, focusing firstly on the specific scales individually, then 
combined specific scales and, lastly, the general scales.
Due to the observational nature of the studies included in this review, it was decided that a 
meta-analytic approach would not be adopted as the number of sources of heterogeneity can 
result in spurious findings (Egger, Davey-Smith & Schneider, 2001).
Characteristics of Included Studies
Characteristics of the 17 studies included can be found in Table 1.
Insert Table 1 here
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Study Design
All 17 studies included in this review are of cross sectional design.
Sample
The total number of participants in each study ranged from 43 to 1084. Thirteen studies had 
under 200 participants, with a mean of 81 participants. The other four studies had large 
samples (Horne et al. 1999; Ross, Walker & MacLeod, 2004; Byrne, Walsh & Murphy, 2005; 
Neame & Hammond, 2005). Samples included fourteen chronic illnesses ranging from 
common disorders such as Asthma and Diabetes to conditions that are relatively rare, such as 
Marfan Syndrome and Haemophilia. The mean age for participants ranged from 36.4 to 74.2.
Beliefs about Medicines Questionnaire
Sixteen studies used the specific scales (necessity and concerns) of the BMQ. The general 
scales have been looked at less often in relation to adherence (47% studies). Four studies 
altered the number of items in the subscales (Webb, Home & Pinching, 2001; Home & 
Weinman, 2002; Butler et al, 2004; Home, Buick, Fisher, & Leake, 2004). The number of 
items in scales is detailed in Table 1. These papers report that internal reliability was not 
impaired by altering scale items. One paper (Butler et al. 2004) added a ‘Benefits’ scale to the 
general section of the BMQ following discussion with the BMQ’s original authors. This scale 
was not described in the paper. It was significantly associated with adherence in a bivariate 
analysis but was not significant in regression analyses. It is not considered in any more detail 
in this review.
Measures of adherence
Studies used a number of different measures of adherence. Fifteen studies used a self-report 
measure of adherence and in three studies this measure was a single item (Home, Sumner,
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Jubraj, Weinman & Frost, 2001; Maidment, Livingstone & Katona, 2002; Neame & 
Hammond, 2005). One study (Byer & Myers, 2000) used objective measures in addition to 
self-report (prescription uptake) and another (Llewellyn, Miners, Lee, Harrington, & 
Weinman, 2003) used adherence diaries as an outcome measure. Only one study (Butler et al.
2004) used solely objective measures of adherence (electronic monitoring).
Other variables measured
Six studies (Horne et al. 1999; Byer & Myers, 2000; Peters, Home, Kong, Francomano & 
Biesecker, 2001; Home & Weinman, 2002; Llewellyn et al. 2003; Butler et al. 2004) included 
the Illness Perceptions Questionnaire (IPQ) and a further two (Ross et al. 2004; Byrne et al.
2005) used the revised version of the IPQ (Moss-Morris, Weinman, Petrie, Home, Cameron 
& Buick, 2002). The IPQ has been developed to encapsulate the illness perceptions 
dimensions of the self-regulatory model. It contains five dimensions measuring identity, 
timeline, consequences, causal factors and control/curability of the illness. It is particularly 
relevant to review the BMQ in relation to the IPQ in order to test whether the BMQ adds to 
the variance explained by illness perception variables. Other, less commonly used, scales are 
described in Table 1.
Reliability and Validity of the Measure
Reliability
A review of any measure needs to consider its psychometric properties. Scales demonstrated 
adequate to good internal reliability as measured by Cronbach’s alpha. The range and average 
of Cronbach’s alphas (computed by D-STAT, Johnson, 1989) is given in Table 2. Test-retest 
reliability (repeated measure after two weeks) is given as measured in the original validation 
study (Home et al. 1999). It has not been examined in any of the other included studies. The
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factor structure of the measure was also explored in the original validation paper but has not 
been evaluated in any study since.
Insert Table 2 here
Validity
Discriminant validity has been assessed in a number of studies demonstrating that the specific 
scales are independent from each other in simple bivariate correlational tests (Trehame, Lyons 
& Kitas, 2004; Aikens, Nease, Nau, Klinkman & Schwenk, 2005; Byrne et al. 2005) and in 
structural equation modelling (Horne & Weinman, 2002). This illustrates that they are 
tapping into different constructs and are not just different ends of the same spectrum. The 
correlation coefficients between the general subscales have been computed less frequently but 
studies report moderate levels of association between the general harm and overuse scales 
indicating that they may be tapping into the same construct (Webb et al. 2001; Trehame et al. 
2004; Byrne et al. 2005). Only two papers assess the degree of relationship between the 
specific and general subscales finding a moderate degree of intercorrelation between them. A 
negative correlation was found between necessity and the general scales, fitting with the 
hypothesised direction (Home et al. 1999; Trehame et al. 2004). However, further reporting 
of the relationships between the subscales and, ideally, testing of the general and specific 
scales in confirmatory factor analysis is required before conclusions regarding their 
interdependence can be drawn.
The means, variance and distribution of scores for each subscale were also examined in 
relation to discriminant validity. Figure 2 provides a pictorial representation of the 
distribution of beliefs across illness populations. The numbers in brackets in the legend of 
Figure 2 identify the study as reported in Table 1. Scales have a minimum score of 0 and a
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maximum score of 5. There was substantial variance in mean scores between different illness 
populations. This would be expected given the diversity of illnesses studied. The specific 
subscales had the largest range of mean scores (Fourteen papers: necessity 1.68[.56] - 
4.28[1.21]; concerns 2.26[.53] - 3.8[.86]) whereas there was less variation between mean 
scores on the general subscales (Five papers: harms 1.42[.48] - 2.1 [.57]; overuse 2.12[.51] - 
2.28[.80]).
Insert Figure 2 here
Around a third of included studies reported the proportion of subjects scoring over the mid­
point on the specific section (Home & Weinman, 1999; Home et al. 2001; Home & 
Weinman, 2002; Butler et al. 2004; Home et al. 2004; Neame & Hammond, 2005) and even 
fewer reported details for the general sections (Home et al. 2001; Webb et al. 2001). Where 
details were reported, a substantial percentage of participants scored above the midpoint on 
the necessity scale (71 - 97%), whereas there were smaller percentages reported for the other 
scales (concerns; 23 -  52%, harms; 33-34%, overuse 12-60%), indicating that responses on 
the necessity scales may be positively skewed. However, studies did not report skewness 
statistics and, as many studies failed to report any details regarding skewness, limited 
conclusions regarding distribution of scores can be drawn.
The difference in treatment beliefs between illness populations is an area that is not well 
developed. Only Home & Weinman (1999) compare the means of different illness conditions 
within one study. They found significant differences in beliefs between illness conditions i.e. 
asthmatic patients had stronger concerns about medication than oncology, renal and cardiac 
patients. They also note that these asthmatic patients also had significantly lower adherence
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to medication. The relationship between medication beliefs and adherence are explored 
further below.
Summary
• The BMQ exhibits satisfactory reliability and validity although further testing and reporting 
of some aspects of reliability and validity is required.
• There is substantial variation in mean scores across different illness populations although 
these have only rarely been systematically investigated. More studies should investigate the 
differences in treatment beliefs by comparing illness groups within one study.
Relationship Between Adherence and the BMQ
The ability of the BMQ to predict adherence in theoretically viable and systematic ways is 
arguably its most useful function. If beliefs about medicine are related to adherence 
behaviour then perhaps intervening in order to change these beliefs could improve adherence. 
The results of the relationships between BMQ scales and measures of adherence are 
summarised in Table 3 along with effect sizes (ES), significance values and details of 
regression analyses.
Insert Table 3 here
Bivariate Analyses
Effect size was categorised according to Cohen’s (1992) conventions. For correlation 
coefficients the index of ES was Pearson’s product-moment correlation coefficient (miniscule 
> .0, small > .1, medium > .3, Large >.5). Where statistics were not reported as correlation 
coefficients they were converted from other test statistics, where these were available, using
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the DSTAT package (Johnson, 1989). Statistically significant results are reported, as are non­
significant results as some studies may have been underpowered. Results were classified as 
incalculable where papers did not report details of analyses (sometimes these were simply 
absent, on other occasions it was because results were just reported as non-significant).
A number of papers have more than one analysis i.e. look at more than one population or 
compare scales against different measures of adherence. These analyses were looked at 
separately. There are 24 individual analyses for the specific scales and 8 for the general 
scales in the seventeen papers reviewed.
Multivariate Analyses
BMQ subscales have been entered into regression analyses in 53% studies, although the 
general subscales were only entered in 18% of studies (as detailed in Table 3). The BMQ 
scales were entered into regression analyses along with demographic, clinical and illness 
perception variables although these combinations differed and were sometimes not fully 
reported. Regression analyses give some indication of the power of the BMQ to predict 
adherence when potential confounding variables are controlled for. However, different types 
of regression models were tested, making comparisons between analyses difficult. These 
different models are each described within the relevant sections.
Results are explored for specific scales individually, combined specific scales and general 
scales in turn. Discussion focuses first on bivariate analyses before multivarariate analyses. 
One study has used Structural Equation Modelling to investigate whether or not the BMQ 
scales mediate between variables from the self-regulatory model in their impact on adherence. 
This paper is discussed at the end of the results section.
37
Specific Scales - Necessity
Effect Size in Bivariate Analyses
Necessity is commonly found to be strongly associated with adherence (significant in 71% of 
analyses). There were 3 large effect sizes for the necessity subscale, 8 medium, 7 small, 2 
miniscule and 4 were incalculable. The largest effect sizes were found in studies using an 
objective measure of adherence. The grounds for the null results are not easy to identify but 
may be related to shorter measures of adherence. Most of the studies with null results 
measure adherence using four items or less in self-reported measures and one study used a 
single item measure of adherence (Home et al. 2004). There was also a tendency for studies 
with larger sample sizes to have smaller effect sizes.
Regression Analyses
The necessity scale remained a significant predictor of adherence in six of the seven 
regression analyses it was entered into. Maidment et al. (2002) found necessity was 
significant at the bivariate level but it was dropped in a backward stepwise regression where 
concerns and other variables were significant (as described in concerns section below). 
Where necessity was significant, two studies used logistic regression, one used forced entry 
analyses and three used hierarchical regression and these results will be presented in turn.
Logistic Regression
Ross et al. (2004) employed multiple logistic regression and found age, BMQ specific 
necessity and two elements of the IPQ-R (emotion and personal control) were most predictive 
of adherence in a population of hypertension patients. This study indicates that aspects of the 
self-regulatory model i.e. illness perceptions, as well as beliefs about the necessity of 
medicines, are associated with increased levels of adherence. They also looked at factors
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associated with specific beliefs. BMQ necessity beliefs were best predicted by a model 
consisting of: three aspects of the IPQ-R (namely perceptions of time, consequences of illness 
and perceptions of cure) as well as age and number of medicines. The authors suggest that 
medication beliefs may mediate the relationship between some illness perceptions, age and 
adherence. This study was rated A in quality evaluation, it had a good sample size and the 
study population was representative of patients attending hospital clinics.
Butler et al. (2004) entered only those variables that were significant in a bivariate screening 
analysis into a logistic regression model for patients with renal transplants. They found a 
transplant from a live donor, low BMQ necessity for immunosuppressants as a group and low 
BMQ necessity for Prednisolone specifically were associated with non-adherence. This study 
was rated A in terms of quality and used electronic monitoring to measure adherence, 
however the sample size was small (58) compared to the large number of variables studied.
Forced Entry Regression
Llewellyn et al. (2003) looked at two types of adherence in Haemophiliac patients -  
adherence to prophylactic treatment and adherence to dose on-demand treatment. Variables 
were entered into regression using the forced entry method. For both types of adherence their 
initial regression model, which included all variables (demographic, clinical, illness 
perceptions and specific BMQ scales) was not significant (see Table 3). However, the 
variance in prophylactic treatment adherence was partially explained by BMQ necessity 
(19%) and IPQ Identity (14%) and a model containing these variables only was significant. 
Adherence to on-demand treatment was only predicted by age (12% variance) and not by 
BMQ scales.
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The results from this study indicate that haemophiliac patients who had stronger perceptions 
of the necessity of treatment were more likely to be adherent despite concerns over the use of 
clotting factor. However, it also showed that age had a strong influence on certain types of 
adherence. This study was rated B in terms of quality. The sample size was small (65) for 
the number of variables measured and the study population was significantly different from 
the clinic population (authors report respondents were significantly older and more likely to 
be HIV positive).
Hierarchical Regression
Trehame et al. (2004) used hierarchical regression analyses to investigate variables related to 
adherence in patients with rheumatoid arthritis. Three demographic and clinical factors were 
entered into the first analysis (children at home, taking steroid medication and total number of 
medications) explaining 21% of the variance in adherence to rheumatology medications. 
Seven psychosocial factors accounted for an additional 43% of the variance. These included 
three aspects of satisfaction with the medical consultation and the four BMQ scales. Out of 
these variables, total number of medicines, increased BMQ necessity and lower BMQ overuse 
beliefs were most associated with the variance in adherence. This study was rated A, 
however it had a comparatively small sample size for the number of variables investigated 
(85).
Byme et al. (2005) also used hierarchical regression analyses to determine variables 
associated with adherence in patients with coronary heart disease. They controlled for 
demographic and clinical variables in step 1, illness perceptions in step 2 and medication 
beliefs (specific and general) in step 3. They found that older age, eligibility for free health 
care (including prescriptions) and IPQ-R chronic timeline were significant until the addition 
of the BMQ. They concluded that illness perceptions were very weakly associated with
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treatment adherence (explaining around 1% of the variance) and there was a small to medium 
effect of medication beliefs on adherence (accounting for about 7% of the variance in 
adherence scores). This was the study with the largest sample size in the review (1084 
participants) and was rated A in terms of its quality.
Home and Weinman (2002) entered 12 variables into a hierarchical regression analysis based 
on data from a sample of asthma patients. Demographic variables (age, gender, educational 
status) explained 6% of the variance in adherence. Clinical factors (number of visits to GP, 
number of hospital admissions, duration of asthma did not add anything to the variance. 
Illness perceptions (IPQ identity, timeline, consequences and cure-control scales) added 
another 13% with medication beliefs (BMQ necessity and concerns) adding a further 17%. 
The authors observed that specific BMQ scales added to the variance explained on top of 
illness perceptions, supporting an extended self-regulatory model that includes beliefs about 
medicines. The authors continued their analysis of the data by looking at relationships using 
stmctural equation modelling, described in more detail below.
Summary
• Overall, the necessity subscale remains a significant predictor of adherence after controlling 
for possible confounding variables.
• It has been suggested that the BMQ necessity scale may mediate the relationship between 
some illness perceptions, age and adherence.
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Specific Scales -  Concerns
Effect Size in Bivariate Analyses
More mixed results have been found between adherence and the BMQ concerns subscale. The 
concerns subscale was significantly related to adherence in 58% of analyses. There were no 
large effect sizes for the concerns subscale. There were 7 medium, 8 small, 2 miniscule and 6 
incalculable effect sizes. Concern scores were not significantly related to adherence in six 
studies (Byer & Myers, 2000; Llewellyn et al. 2004; Barnes, Moss-Morris and Kaufusi 2004; 
Butler et al. 2004; Trehame et al. 2004; Aikens et al. 2005). These studies were adopting 
some of the more objective or substantial self-report measures of adherence.
Regression Analyses
The BMQ Concerns scale was significant in three out of seven regression analyses. As 
mentioned above, concerns regarding medication were significantly related to adherence, as 
well as necessity beliefs, illness perceptions and other variables, in both Byme et al. (2005) 
and Home and Weinman’s (2002) analyses. Maidment et al. (2002) is the only study to find 
that medication concerns remained a significant predictor of adherence when necessity beliefs 
did not. They entered seven variables into a backwards linear regression model using data 
from a sample of depressed older adults. BMQ Necessity, the general health questionnaire 
(GHQ) and the Geriatric mental state schedule depression scale (GMSS-DS) were not 
significant in the model. The model, accounting for 27.1% of the variance in adherence to 
antidepressant medication, included BMQ concerns, a questionnaire on patient education 
(QPE), the Mini mental state examination (MMSE) and a global side-effect burden measure. 
Therefore concerns were more related to adherence than necessity in this population. This 
study was rated as B as there were some differences between respondents and non-
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respondents (respondents were significantly younger), adherence was measured using one 
item, and sample size was small for the number of variables measured.
Ross et al (2004) investigated the variables that predicted medication concerns. This is 
perhaps surprising given that the authors found that the association between BMQ concerns 
and adherence did not remain statistically significant in their multivariate analyses (i.e. when 
age, BMQ Necessity and aspects of the IPQ were taken into account). However, they found 
that a model comprising of: BMQ harm, BMQ overuse, IPQ emotional response, IPQ 
consequences and age best predicted medication concerns. They suggest that general beliefs 
about medication may indirectly influence adherence through specific concerns. This is in 
line with the model proposed by Home et al. (1999).
The finding that concerns were not strong predictors of adherence was contrary to some 
authors’ expectations. Llewelyn et al. (2003) and Butler et al. (2004) were surprised that 
concerns about medication were not more strongly associated with non-adherence given the 
risk of infection using clotting factor or the side effects of immunosuppressants. They 
suggest that a salient belief in the need for the medication may overrule concerns about 
troublesome side effects.
Summary
• It appears that concerns about medicines are less strongly associated with adherence than 
necessity but they are more salient in some populations than others.
• Concerns are not predictably associated with adherence in conditions taking medication 
with greater side effects.
• It has been suggested that concerns may mediate the relationship between general BMQ 
scales and adherence.
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Necessity-Concerns Differentials (NCD)
Effect Size in Bivariate Analyses
Some studies have found a stronger association between adherence and the specific scales 
when they combine the necessity and concerns scales into a differential (NCD). A NCD was 
employed in 5 of the studies included in this review (Home & Weinman, 1999; Peters et al. 
2001; Home et al. 2004; Aikens et al. 2005; Neame & Hammond, 2005). These five papers 
produced 9 separate analyses and in each of these the NCD was always found to be 
significantly associated with adherence (5 medium effect sizes, 3 small and one incalculable 
result).
Regression Analyses
A NCD was entered into two analyses and was significant in one (Home & Weinman, 1999). 
Their stepwise linear regression model of adherence to medication across a variety of illness 
groups demonstrated that the necessity-concems differential explained most of the variance 
(19%), followed by illness group (asthma and cardiac) and age. This paper was also 
evaluated as an A grade paper with a large sample overall and no evidence of bias in its 
sample. The NCD was not significant in Peters et al. (2001), where it was entered into a 
regression with age, palpitations, chest pain, headaches, BMQ harms, BMQ ovemse and 
BMQ concerns. This study was rated as C on quality criteria. It had a reasonable sample size 
T74) but a poor response rate (50%) and any differences between the study population and 
.he clinic population were not discussed.
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Summary
• Initial investigations suggest that a composite of necessity and concern scores may be a 
helpful way of understanding cost-benefit decisions regarding adherence behaviour but, as it 
has been employed only infrequently, further analysis is required before firm conclusions can 
be drawn regarding its utility.
General Scales
Effect Size in Bivariate Analyses
The overuse scale was significantly related to adherence in 44% of analyses (Home et al. 
1999; Peters et al, 2001; Webb et al. 2001; Aikens et al. 2005). It had a medium effect size in 
2 of these analyses, 3 small, 1 miniscule and 3 were incalculable. The harms scale was 
significantly related to adherence in 22% analyses (Peters et al. 2001; Trehame et al. 2004), 
producing 1 medium, 4 small, 1 miniscule and 3 incalculable effect sizes. A harms-overuse 
differential was not significant in the one study that had used it (Aikens et al. 2005).
Regression Analyses
The BMQ general harm subscale was a significant contributor in one out of three regression 
models (Peters et al. 2001), as was the BMQ overuse subscale (Trehame et al, 2004).
Peters et al. (2001) found younger age, increased palpitations and increased general harms to 
be the variables most strongly associated with adherence in patients with Marfan syndrome 
using multivariate analysis. In this study it appears the patient’s beliefs about medicines in 
general as intrinsically harmful are most associated with adherence. The authors relate this 
finding to medicines being perceived as a threat to self-reliance and a reminder of the 
permanence of their medical condition. This study was rated C as discussed above.
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Trehame et al. (2004) found the BMQ general overuse scale and not specific concerns 
predicted adherence for patients with rheumatoid arthritis. The authors suggest that 
participants may have played down the specific concerns about medicines because they 
believed they were necessary whilst maintaining beliefs that medicines are overused in 
general.
Summary
• These findings indicate that BMQ general scales are not strongly associated with adherence 
to current medication, however more studies are required to investigate the general scales in 
multivariate analyses before firm conclusions can be drawn.
• Patients’ beliefs about medicines in general may not always be related to their beliefs about 
specific medicines.
Structural Equation Modelling
Although the BMQ has been entered into regression analyses and has been shown to add to 
the variance in predicting adherence, there are limitations to regression analyses that prevent 
fully testing the extent to which the data fit the predicted pattern of relationships between 
medication beliefs and adherence. All of the variables that are entered into a regression 
model are allowed to correlate with all of the other variables. Although this allows the 
researcher to rule out potential confounding between variables it can have unforeseen and 
unwanted effects. Even where independent variables do not correlate significantly, the small 
degree of overlap that does exist can introduce distortions into the model. Perhaps more 
frustrating for the analyst is when they theorise that some of the independent variables have 
their effects mediated through some of the other independent variables. In these instances, the
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true importance of a variable can be obscured by the multiple regression approach, as only its 
unique contribution to the variance of the dependent variable is tested. Structural equation 
modelling, on the other hand, is superior to regression analyses as the analyst can specify 
precisely which variables are correlated and which are independent. It also allows for direct 
and indirect effects to be included thus enabling model specification that corresponds exactly 
to the theoretical model.
Home and Weinman (2002) used structural equation modelling (SEM) to examine the 
relationships between illness perceptions and specific medication beliefs in explaining non­
adherence to asthma medication. They demonstrated that the specific necessity and concerns 
scales influence adherence directly. They also found that the relationship between some 
illness perceptions and adherence were mediated by medication beliefs i.e. individuals who 
believed their asthma was a less chronic condition were less likely to believe in the necessity 
of their treatment, and were then less adherent to it.
The findings of Horne and Weinman’s (2002) study are interesting as it suggests that illness 
perceptions may not appear significantly related to adherence in a regression analysis that 
included medication beliefs. It also suggests that regression analyses that enter illness 
perception variables before medication beliefs weaken the effect of medication beliefs e.g. 
Byrne et al. (2005). Taking their results one step further, their SEM implies that targeting an 
adherence intervention at changing illness beliefs will improve adherence by subsequently 
changing medication beliefs.
The Home and Weinman (2002) study suggests that the strength of the self-regulatory model 
to explain adherence is improved by extending it to include medication beliefs, and provides 
preliminary empirical support for an extended self-regulatory model of treatment adherence.
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Illness perceptions and beliefs about medicines have repeatedly been shown to affect 
adherence. Structural equation modelling allows the literature to move forward by 
demonstrating how these variables relate to each other. More studies are required in order to 
replicate these findings and also to expand this model further.
Summary
• Structural Equation Modelling provided further evidence that BMQ specific beliefs may 
medicate the relationship between illness perceptions and adherence.
• The model described in Home and Weinman (2002) also suggests that the strength of the 
self-regulatory model to explain adherence is improved by extending it to include medicine 
beliefs.
DISCUSSION
This review set out to investigate the psychometric properties of the BMQ with particular 
emphasis on criterion validity i.e. how the BMQ scales are associated with adherence to 
medicines prescribed in chronic illness populations. The BMQ was found to exhibit 
satisfactory reliability and validity, although it was acknowledged that further testing and 
reporting of some aspects of reliability and validity is required. There are substantial 
variations between mean scores across different illness populations, although these cannot be 
easily summarised due to heterogeneity within the study sample.
Despite the variation in means, the BMQ is consistently associated with adherence across a 
variety of chronic illness populations and these relationships are, for the most part, in 
directions that were predicted by theory. The necessity scale appears to be the most strongly 
associated with adherence in the regression analyses examined here. However there is
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variation, in that some regression analyses find other scales are the most potent predictor of 
adherence. Perhaps this is a consequence of the diverse nature of the illnesses and treatment 
regimens studied. Nonetheless, the relationships can sometimes seem surprising. For 
example, the weak relationship between specific concerns and adherence in populations with 
high medication side-effects or risk. It is also surprising that beliefs that medicines were 
generally harmful were more predictive of non-adherence than specific concerns in a sample 
of patients with rheumatoid arthritis, where most other studies have found general concerns to 
be mediated through specific concerns.
The results of this review have some interesting implications for understanding adherence 
behaviour. Firstly, regression and SEM analyses appear to indicate that the BMQ mediates 
the effect of particular variables on adherence. Beliefs about medicines may therefore be 
more directly related to adherence than other variables such as age and illness perceptions (as 
measured by the IPQ). Secondly, there is growing evidence that adding the BMQ to the self- 
regulatory model increases its explanatory power for adherence. These findings highlight the 
importance of medication beliefs in determining adherence behaviour.
These results would suggest that interventions to improve adherence may profit from focusing 
on medication beliefs. The literature search that detected the papers included in this review 
did not discover any papers describing interventions that focused on altering medication 
beliefs per se. However, studies are starting to use the BMQ to assess whether medication 
beliefs change when intervening to improve adherence. The few studies that there are found 
that medication beliefs do change as a result of these interventions (Higgins, Livingston & 
Katona, 2004; Theunissen, de Ridder, Bensing & Rutten, 2003). Interestingly, Theunissen et 
al. (2003) found that discussing illness representations in a G.P. consultation reduced 
concerns about hypertension medicines, fitting with the finding of this review that these
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concepts are related to each other and that perhaps illness perceptions are mediated through 
medication beliefs. Unfortunately, this study did not look if these reductions in medication 
concerns actually improved the adherence to anti-hypertensive drugs.
Limitations of Reviewed Papers
There are several limitations to the evidence base reviewed above; particularly relating to 
study design, measures used and statistical power which may limit the conclusions of this 
review.
Study Design
The cross sectional design of studies only allows for the analysis of the association between 
beliefs about medicines and adherence at a single point in time therefore limiting inferences 
that can be made about the direction of cause between variables.
Measure of Adherence
There is debate in the literature as to the relative benefits of self-report compared to objective 
measures of adherence. Objective measures such as electronic monitoring or blood assays 
are considered the ‘gold standard’ but are often impractical and expensive. Self-report 
measures have been compared to objective measures and have been found to be a useful 
indicator of adherence (Choo, Rand, Inui, Lee, Cain, Cordeiro-Breault, Canning & Platt, 
1999). Self-reports are also the method that clinicians use routinely to measure adherence in 
practice. In some sense therefore, self-reports may have more ecological validity than more 
objective measures. It is nonetheless worth noting that the majority of the studies here are 
using a measure of adherence that may be less sensitive than objective measures. This extra 
sensitivity may be responsible for the finding that the studies that used more objective
50
measures of adherence had larger effect sizes. Additionally, some studies included in this 
review have used only one item to measure adherence. This obviously limits the range of 
possible responses and is likely to increase the amount of error in the measure thereby 
affecting statistical power. All studies using a single item to measure adherence had some 
non-significant results.
Statistical power
It is known that statistical power can be maximised by ensuring an adequate sample size, 
avoiding score range restriction, using reliable measures, and using homogeneous subjects 
populations (Hallahan & Rosenthal, 1996). Some of the studies included in this review have 
limitations in these areas, which are likely to affect the power and validity of results. In 
particular, some studies had a small sample size for the number of variables analysed which 
can limit the power of the study to detect a significant effect (Type 2 error).
Limitations of Review
This review may be limited by the following factors:
Guidelines for Evaluating Study Quality
As discussed earlier, there is no concensus on quality evaluation criteria for cross sectional 
observation studies, and few exclusion criteria, so it is difficult to provide standardised 
evaluations of study quality. Focusing on published literature provides some reassurance of 
minimal study quality but this can result in biased results from the publication process itself.
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Publication Bias
Publication bias is a common problem in systematic reviews as there is a trend towards the 
publication of positive results, resulting in effect sizes being an overestimation of the true 
effect (Easterbrook, 1991). However, because many of the studies included more than one 
scale of the BMQ, both significant and non-significant results are considered in this review. 
Nonetheless, the results of this review suggest a trend towards larger studies reporting smaller 
effect sizes. This may indicate that smaller studies that find smaller effect sizes, and therefore 
non-significant results, may not have their studies published.
Recommendations for Future Research
Study Design
Studies should adopt longitudinal design, or use structural equation modelling, to allow 
analysis of whether beliefs about medicines are causal or the result of adherence behaviour.
Intervention Studies
The finding that beliefs about medicines are reasonably predictive of adherence is potentially 
very important given that reviews highlight the paucity of effective interventions to improve 
adherence and call for the development of innovative approaches (Haynes et al. 1996, 
McDonald et al. 2002). Intervention studies are needed to test whether changing medication 
beliefs can alter adherence behaviour. This review demonstrates that certain beliefs are more 
strongly associated with adherence than others. It is suggested that focusing on improving the 
perceived need for medication is likely to have a stronger effect on adherence than reducing 
medication concerns, although this might vary across illness groups.
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SUMMARY
• There is evidence that beliefs about medicines can be measured in a systematic 
way.
• The BMQ scales appear to be related to adherence in correlational studies, 
although we cannot be certain about the direction of cause as these studies 
were not prospective.
• Certain aspects of beliefs are more prominent predictors of adherence than 
others i.e. perceived need for a specific medicine more than concerns or 
general views on medication, and it would be worth focusing on these beliefs 
in any future interventions.
• Beliefs about medicines continue to be predictive of adherence after 
controlling for a variety of potential confounding variables.
• Beliefs about medicines may mediate the effect of other factors, such as age 
and illness perceptions, in predicting adherence.
• The BMQ should now be used in more intervention studies to assess if altering 
beliefs can alter medication taking behaviour.
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Chapter 3: Major Research Proposal
Adherence to Pharmacological Treatment of Non-Malignant Chronic Pain: 
The Role of Illness Perceptions and Treatment Beliefs
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Summary of Project
Objective. The aim of this study is to identify the degree to which illness perceptions and 
treatment beliefs explain variations in reported adherence to medication prescribed for the 
treatment of non-malignant chronic pain. It will also test the applicability of an extended 
version of the self-regulatory model to the chronic pain population.
Design and method. A cross-sectional design will be employed. Patients attending chronic 
pain clinics will complete validated questionnaires assessing their illness perceptions, beliefs 
about medication and reported adherence to medication. Data will be analysed using 
structural equation modelling and hierarchical regression analyses.
Keywords. Illness perceptions: Treatment beliefs: Chronic pain: Adherence: Self-regulatory 
model: Structural equation modelling
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Introduction
Chronic Pain
Chronic pain has been defined as ‘pain that either persists beyond the point at which healing 
would be expected to be complete or that occurs in disease processes in which healing does 
not take place’ (Clinical Standards Advisory Group, 2000). The term is used to encapsulate a 
variety of conditions such as fibromyalgia, chronic low back pain and rheumatoid arthritis. 
Conditions such as chronic low back pain are increasing in prevalence in industrial society 
and are considered to be a major source of lost income due to disability (Karjalainen et al, 
2004). Chronic pain is resistant to treatment (Guzman et al, 2004), and a significant problem 
with non-adherence to prescribed medication has been identified (Kendrew et al. 2001). Non­
adherence to prescribed medications is well documented in the general medical literature 
(WHO, 2003), and a recent review indicates that around 50% of patients fail to receive the 
full benefit of prescribed medications through non-adherence (Rogers & Bullman, 1995).
Adherence Research
Until recently, research into medication use focused on the concept of compliance. 
Compliance is defined as the extent to which a patient’s behaviour coincides with medical 
advice (Haynes, 1979). It reflects the traditional biomedical model of healthcare, and neglects 
the psychological and social aspects of illness. The term adherence is more associated with 
the psychosocial model of health care, which sees adherence as an intricate series of 
behaviours (Ley, 1997). There has been a corresponding shift in research from an atheoretical 
focus on patient characteristics (e.g. sociodemographics, clinical factors), which ignores 
patient’s views, to the development of theory driven models of health behaviour.
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Factors Predicting Adherence in Chronic Pain
Although there is evidence that many chronic pain patients do not adhere to their prescribed 
medicines, the literature examining why this is the case is under-developed, compared to 
research that has examined non-adherence in other medical populations. Proposed reasons for 
non-adherence in chronic pain are largely related to patient characteristics and include 
demographic (age, socio-economic status), clinical (illness severity, chronicity of illness) and 
practical (collection of prescriptions) factors. The influence of psychological factors (beliefs 
about illness and medication) has been barely explored. However, clinical and health 
psychology research has made considerable advances in exploring the psychological factors 
that determine people’s adherence behaviour in other chronic conditions.
The Application o f Theoretical Frameworks to Adherence Behaviour
A number of theories have been proposed to explain how psychological factors influence 
health behaviours such as adherence. Expectancy-value models, such as the Health Belief 
Model, propose that the likelihood of a particular behaviour will depend on the individual’s 
expectation that the behaviour will result in a positive outcome and on the value of that 
outcome. Much research has applied the Health Belief Model to health behaviours but there 
is growing evidence to suggest that cognitive models, such as the Theory of Planned 
Behaviour (TPB), explain more of the variance in health behaviours (Connor and Armitage, 
2000). The TPB describes the relationships between beliefs, attitudes and behaviours, and 
postulates that peoples’ intentions are the best predictors of their health behaviours. A review 
by Sheeran (2005) provides evidence that the TPB reliably predicts around 28% of variance in 
behaviour. These models have been successfully applied to peoples’ adherence to a variety of 
medical regimens, from attendance at breast cancer screening (e.g. Rutter 2000), to dietary 
and exercise adherence in diabetes (e.g. Glasgow et al. 1986).
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The Self-Regulatory Model
However, these models have been criticised as not providing complete explanations of 
specific illness behaviours (Marteau, 1995) and other models have been put forward which 
aim to address this criticism by including these variables. The best example of this is the 
illness representation model developed by Leventhal and colleagues (Leventhal et al. 1980; 
Leventhal et al. 1992). This model is often described as a self-regulatory model (SRM), as it 
proposes that the individual attempts to regulate their behaviour during an illness threat, such 
as perceiving a symptom (see Figure 1).
Insert Figure 1 here
Two interacting parallel processing pathways are proposed in the SRM. It is suggested that 
the first processing pathway is a cognitive representation of the illness and the coping 
strategies that are employed as a result of the illness representation. The second pathway is an 
emotional representation of the illness and the coping strategies employed to deal with it. It 
is proposed that coping effectiveness is appraised, impacting on cognitive and emotional 
representations, and future coping responses. As a result, the SRM is a dynamic system 
explaining the representation of the illness, and coping strategies employed as a result of an 
illness threat.
Evidence Supporting the Application o f the SRM to Adherence
A review by Hagger and Orbell (2003) indicates that there are theoretically predictable 
relationships between illness cognitions, coping and outcomes (highlighted in bold in figure
1). The SRM has been applied to explore adherence to treatment in various chronic illness 
populations (e.g. Jessop and Rutter, 2003, Ross et al. 2004, Whitmarsh et al. 2003), with
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adherence being viewed as a coping response. However, there is a paucity of research 
examining illness representation variables, and their effects on treatment adherence, in the 
chronic pain literature.
The Dimensions o f Illness Representations
Illness representations are proposed to be structured around 5 dimensions -  that is the 
identity, timeline, consequences, causal factors and control/curability of the illness. The 
relative role of each dimension in predicting adherence has been investigated in a number of 
studies. Home and Weinman (2002) and Walsh et al. (2004) found that negative perceived 
consequences of illness were more associated with non-adherent behaviour, whereas Ross et 
al. (2004) found that belief in personal ability to control illness was the most important 
dimension in predicting adherence to hypertension medication.
Hagger & Orbell (2003) looked at the relationship between illness cognitions and illness 
outcomes in their review and conclude that it could be predicted that a chronic timeline, more 
serious consequences, a strong illness identity and high symptomatology are associated with 
poorer adjustment and outcomes, whereas a higher perceived level of controllability/curability 
would be associated with better adjustment. However, Hagger and Orbell (2003) also 
highlight that the pattern of beliefs vary across illnesses and ought to be explored for different 
illness groups.
Most papers in this review use the Illness Perceptions Questionnaire (Weinman et al. 1996) to 
measure cognitive representations. Studies have more recently used the revised version of 
this scale to measure emotional representations as well as the cognitive dimensions described 
above, enabling a comprehensive assessment of the SRM (Moss-Morris et al. 2002). One
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such study indicated that higher emotional reactions are linked to poorer adherence (Ross et 
al. 2004).
Modelling the SRM
Although the value of the SRM in explaining adherence in chronic illness has been 
demonstrated by a number of studies, these studies have used regression analyses, which 
despite being depicted using path diagrams, do not allow for formal tests of mediating 
relationships. Few studies have tested fully the extent to which the data fit the predicted 
relations between illness representations and adherence. However, Home and Weinman 
(2002) used stmctural equation modelling to examine the direct and indirect relationships 
between illness perceptions and medication beliefs in explaining non-adherence to asthma 
medication. They demonstrated that illness perceptions influence adherence both directly and 
indirectly through medication beliefs i.e. individuals who believed their asthma was a passing 
condition were less likely to support the necessity of their treatment, and were less adherent to 
it. Figure 2 reproduces their model.
Insert Figure 2 here
The weakest correlation was between Illness Timeline and Illness Consequences (.19). Other 
correlation coefficients ranged from .25 to .38 (small to moderate correlations). This study 
suggests that the strength of the SRM to explain adherence is improved by extending it to 
include a measure of treatment beliefs, and provides preliminary empirical support for the 
extended self-regulatory model of treatment adherence.
The results of a search of the literature indicate that there have been no studies using the SRM 
to predict adherence to treatment in chronic pain, although the findings of a study by Hobro et
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al. (2004) support the use of the SRM to cluster chronic pain patients. This study will follow 
a similar design to that applied in Home and Weinman (2002), in that it will examine the role 
of illness perceptions and treatment beliefs in explaining adherence. However, the extended 
self-regulatory model will be applied to a chronic pain population, thus initiating the 
empirical testing of this model in a new population.
Hypotheses:
1) Adherence to prescribed medication will be explained by illness perceptions: with 
perceptions of a chronic timeline, more serious consequences, a strong illness identity 
and more symptoms and higher emotional response being associated with poorer 
adherence, and higher perceived levels of controllability/curability being associated 
with better adherence.
2) Adherence to prescribed medication will be related to beliefs about medication. 
Adherence will be positively correlated with patients’ perceptions of the necessity of 
prescribed medication and negatively correlated with concerns about potential 
negative effects.
3) Beliefs about medication will add to the proportion of variance in adherence that is 
explained by illness perceptions, clinical factors and demographic variables.
4) The extended SRM model, as proposed in Home and Weinman (2002), will be a good 
fit to the data (as judged by a variety of fit indices).
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Study Design
a) Participants
Inclusion criteria:
1) Participants will include all patients with non-malignant chronic pain that are 
attending a pain clinic and receiving prescribed medication for pain at one of the 
Glasgow hospitals. In terms of the types of pain conditions sampled, the population 
is likely to be heterogeneous. However, it will be an ecologically valid sample of the 
pain clinic population. Furthermore, there are no a-priori, theoretical reasons for 
thinking that the model is more relevant to certain non-malignant pain conditions than 
it is to others.
Exclusion criteria:
1) Patients with pain that is associated with malignant disease will be excluded, as 
their illness perceptions are likely to be different from the rest of the pain 
population and they are a minority of the pain population seen in the chronic pain 
clinics.
2) Age limits will be set. Recruited patients will be over 18 and under 65, as 
adherence behaviours have been found to differ in children and older adults (e.g. 
Hughes, 2004), and there are different consent issues in these populations.
3) As this is a self-completion questionnaire study, patients will be excluded if they 
cannot understand spoken and written English. Time pressures on the consultant 
anaesthetists make it impractical for questionnaires to be read out to patients with
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literacy difficulties. However, if the patient has a translator or interpreter with 
them who is prepared to help the patient complete the questionnaire, the patient 
will be included in the study.
b) Recruitment
Patients will be accessed from the weekly chronic pain clinics that run at a number of 
hospitals in Glasgow (Gartnavel General, Stobhill, Royal Infirmary, Victoria and Southern 
General Hospitals), focusing recruitment on 3 sites (Gartnavel General, Royal Infirmary and 
Stobhill). All patients who have been prescribed medication for their pain by their consultant 
anaesthetist will be invited to take part in the study. An audit of patients being seen by 
anaesthetists has been conducted. Results estimate an average recruitment rate of 15 patients 
per clinic, per week. Based on this estimate, recruitment will take place over an 8 week 
period, approximately.
c) Measures
A major difficulty in this area of research is the variety of instruments used to measure the 
independent and dependent variables. This diversity limits cross-study comparisons, and 
impedes the progress of research. Consequently, this study will adopt standardised measures 
to address the independent variables of illness perceptions and treatment beliefs. It will also 
adopt a standardised self-report measure of adherence. Self-report measures of adherence 
have been found to differ from objective measures of adherence by around 30% in chronic 
pain patients. For example, Bemdt et al. (1993) found 70% correspondence between self- 
reports of adherence to medication in chronic pain and urine toxicology screening. Whilst 
toxicology screening would provide the most accurate way of measuring adherence, self­
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report is recognised as an acceptable estimate of adherence when objective measures are 
ethically inappropriate, or practically unviable (Stephenson, 2003).
At assessment patients would be asked to complete a questionnaire pack including:
1) The Illness Perceptions Questionnaire -  Revised, IPQ-R (Moss-Morris et al. 2002). 
The Illness Perceptions Questionnaire (IPQ) has encapsulated the illness perception 
components of the SRM. The IPQ-R was chosen over the original Illness Perceptions 
Questionnaire (Weinman et al. 1996) as it has been validated on chronic pain patients and 
found to have good reliability and validity (Cronbach’s alpha’s for each of the subscales 
range from .79 to .89 and test-retest correlations from .46 to .88). The IPQ-R evaluates the 5 
original dimensions of the SRM but breaks timeline and control beliefs into two scales and 
includes a measure of emotional response to illness. Scores for eight of the nine scales 
(identity, timeline, timeline cyclical, consequences, personal control, treatment control, 
coherence and emotional representation) are summed individually to assess the relative 
contributions they make to adherence. The cause section is not treated as a scale but analysed 
as separate items in accordance with authors’ recommendations (Moss-Morris et al. 2002).
This study will use the standardised Chronic Pain version of the IPQ-R. The questionnaire
therefore does not need to be altered to suit the client group.
2) Beliefs about Medicines Questionnaire, BMQ (Horne et al. 1999)
The BMQ will be employed to measure patients’ beliefs about prescribed medication for pain. 
The BMQ contains two scales: one assessing the patient’s concerns about their medication the 
other their beliefs about the necessity of their medication. It has been validated on other 
chronic illness populations and shows good reliability and validity (Cronbachs alpha .75 and 
.80 and test-retest .76 and .77 when validated on asthmatic patients). It has been used to
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assess treatment beliefs in previous studies (e.g. Home and Weinman, 2002), and has also 
been used to assess chronic pain patients’ beliefs about their medication (Hobro et al. 2004).
3) Medication Adherence Report Scale. MARS (Home and Hankins, 2001).
The MARS is a 5 item self-report questionnaire that has been used in published papers to 
assess the degree of adherence to medications prescribed for chronic pain (Home and 
Weinman, 2002). The frequency of non-adherent behaviours (deciding to miss a dose, 
forgetting to take a dose, altering the dose, stopping taking doses for a while and taking less 
than instructed) is measured on a 5-point Likert-type scale. Scores are summed to give a 
continuous measure of adherence or can be split into categories of ‘high’ and Tow’ adherence.
The scale can produce both continuous and dichotomised (good/poor adherence) scales. This 
study will use a continuous scale, as important material is lost when the scale is dichotomised 
(Oppenheim, 1992). Convergent validity has been assessed between the BMQ and MARS 
with negative correlations between the BMQ-concems and MARS and positive correlations 
between BMQ-necessity and MARS (Home and Hankins, 2001).
4) Pain Numerical Rating Scale. PNRS
Numerical rating scales have been recommended by a leading international group of pain 
researchers to measure pain in chronic pain trials (McQuay, 2004). The PNRS provides a 
measure of the severity of the patient’s pain by asking them to rate their pain on a scale of 0 to 
10, where ten indicates the most severe pain.
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d) Design and Procedure
All patients receiving a clinic appointment during the recruitment phase of the study will be 
sent information about the study and a consent form no later than two weeks before their 
appointment. Anaesthetists will ask patients who are currently taking medication for chronic 
pain to take part in the study during their routine consultation. Participants will be given the 
opportunity to ask questions about the study before signing the consent form and completing 
the questionnaires detailed above.
e) Settings and Equipment
Recruitment will be carried out in the pain clinics. The researcher will require access to paper 
and a photocopier. A computer package will also be required for statistical analysis such as 
EQS (ver 6.1: Bentler, 1995).
f) Power Calculation
Bentler and Chou (1987) recommended 15 participants per variable as a guideline for sample 
size in structural equation modelling. Home and Weinman (2002) have 5 variables in their 
model (timeline, consequences, necessity, concerns, adherence rating) so replicating their 
model would require 75 participants.
A more formal calculation of sample size of 216 patients has been determined using the 
UCLA website. This is based on a Null hypothesis value of 0, an alternative hypothesis value 
of .19 (using the weakest correlation from Home and Weinman, 2002), and using
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participants will be aimed for to allow for attrition and missing data.
g) Data Analysis
The study will employ:
1) Descriptive statistics and Cronbach alpha values will be provided for each scale to 
demonstrate whether scales were internally reliable.
2) Scores on scales will be checked to see if they are normally distributed.
3) Pearson correlation coefficients will test the relationship between illness perception 
dimensions and adherence (hypothesis 1).
4) Correlation coefficients will also be employed to test hypothesis 2 i.e. adherence will 
be positively correlated with beliefs about the necessity of medication and negatively 
correlated with concerns.
5) Hypothesis 3 will be tested by hierarchical multiple linear regression.
6) The relationships between the SRM variables that are specified in Home and 
Weinman’s (2002) model, will be tested using a Stmctural Equation Modelling 
approach using the statistical package EQS (ver 6.1: Bentler, 1995). This approach 
also allows the overall fit of the model to be evaluated as well as testing the 
significance of mediated pathways.
Practical Applications
This study is the first to explore the specific illness and treatment representations that most 
strongly affect adherence in the chronic pain population. It is also the first stage of a 
continuing research programme in the Glasgow chronic pain service. The results of this study
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can be used to improve practice. For example, clinicians working with chronic pain patients 
could improve adherence to prescribed medication by identifying and challenging problematic 
representations. The impact of altering illness and treatment representations on adherence 
could be evaluated by further studies.
Ethical Issues
1) The proposed study will involve patients filling out a number of straightforward 
questionnaires. It is proposed that each set of responses will be coded to retain 
confidentiality and entered onto a secure computer database. Original transcripts will 
be kept in a locked filing cabinet.
2) The study will not affect the treatment that participating patients receive.
3) It is likely that non-adherent behaviour will be reported on the Medication Adherence 
Scale. This information will be a general overview of the way a patient uses 
medication and not specific details on what medication they are not taking correctly. 
We will therefore be unable to identify any specific concerns about medication. Thus 
patients will be informed that no action will be taken if they report non-adherent 
behaviour. The information collected is providing a snap shot of patient's behaviours 
and no intervention will be offered to alter behaviour. This will also be made clear in 
the patient information leaflet.
4) Access to details i.e. age, gender, diagnosis for patients who opt out of study would be 
preferable to allow for comparison but may pose ethical problems. Guidance notes for 
the Local Research Ethics Committee state that anonymised, aggregrated patient 
information can be used in NHS studies without the patient’s express consent.
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Figure 1 The self-regulatory model
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Amendments to proposed project
Amendment 1: ‘Age limits will be set. Recruited patients will be over 18 and under 65, as 
adherence behaviours have been found to differ in children and older adults (e.g. Hughes, 
2004), and there are different consent issues in these populations. ’
The upper age limit for participants was removed as a substantial proportion of clinic patients 
were over 65 and it was felt that excluding these patients would reduce the ecological validity 
of the study. Approval for the change was granted from the Ethics Committee (appendix 4.3). 
There was not thought to be any different consent issues but the literature has mixed findings 
on rates of adherence in older adults, therefore the effects of age on adherence were explored 
in the study’s results.
Amendment 2: ‘All patients receiving a clinic appointment during the recruitment phase o f  
the study will be sent information about the study and a consent form no later than two weeks 
before their appointment. Anaesthetists will ask patients taking medication for chronic pain 
to take part in the study during their routine consultation. Participants will be given the 
opportunity to ask questions about the study before signing the consent form and completing 
the questionnaires detailed above. ’
The local ethics committee recommended that patients be given the option of opt-in to the 
study as opposed to informed consent to reduce the likelihood of influence from the doctor- 
patient relationship. Patients therefore received a patient information sheet (appendix 4.2) 
before clinic attendance and could opt-in to the study at their clinic appointment.
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Abstract
Objective. To identify the degree to which illness perceptions and medication beliefs explain 
variations in reported adherence to medication prescribed for the treatment of non-malignant 
chronic pain and to test the applicability of an extended version of the self-regulatory model 
(SRM) to the chronic pain population.
Design and method. A cross-sectional design of 217 patients attending a chronic pain clinic, 
who completed validated questionnaires assessing their illness perceptions, medication beliefs 
and reported adherence to medication.
Results. Perceptions of illness (pain) as chronic, uncontrollable and unremitting (not cyclical) 
were associated with greater adherence to medication, fewer concerns about medication and a 
belief that treatment was necessary. Illness and medication beliefs each added 3% to the 
variance in adherence explained by demographic and clinical variables in a regression analysis. 
Structural equation modelling supports an extended SRM for chronic pain. It suggests that 
patients holding perceptions of serious consequences of pain and high levels of emotion have 
more concerns about medication and are less adherent. Perceptions of serious consequences 
of illness are also associated with stronger beliefs about the necessity of medicines and greater 
adherence.
Discussion. Beliefs about illness and medication are associated with adherence to treatment in 
chronic pain and this can be explained by an extended SRM. These results are preliminary and 
require replication. Further studies should further explore the role that emotion has on coping 
strategies in chronic pain. Interventions should focus on altering unhelpful beliefs that reduce 
adherence.
Keywords. Illness perceptions: Medication beliefs: Chronic pain: Adherence: Self-regulatory 
model: Structural equation modelling
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Introduction
Chronic Pain
Chronic pain has been defined as ‘pain that either persists beyond the point at which healing 
would be expected to be complete or that occurs in disease processes in which healing does not 
take place’ (Clinical Standards Advisory Group 2000). The term is used to encapsulate pain 
associated with a variety of conditions such as fibromyalgia, chronic low back pain and 
rheumatoid arthritis. Chronic pain has a high prevalence and an influential report asserts that it 
affects 18% of Scottish people (McEwan, 2004). The Clinical Standards Advisory Group 
(2000) advised that although ‘cure’ is seldom an option in chronic pain, a great deal can be 
done to treat pain and alleviate its effects.
Patients experiencing chronic pain in Scotland have high rates of mental health problems, high 
utilisation of health services and high unemployment (Haetzman et al. 2003). Chronic pain has 
proved resistant to treatment (Guzman et al, 2004), and this is associated with significant non­
adherence to prescribed medication (Kendrew et al. 2001). There is a clear requirement to 
investigate factors that predict non-adherence in this population, thereby facilitating 
interventions to improve adherence. Improving the management of chronic pain would have 
substantial benefits to the patient, health services and the economy.
Factors Predicting Adherence in Chronic Pain
The literature examining non-adherence in chronic pain is under-developed, compared to 
research that has examined non-adherence in other medical populations. In the wider literature, 
patient characteristics (e.g. demographic and clinical factors) and practical factors (e.g. 
collection of prescriptions) have been proposed to influence adherence. Psychological factors
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(e.g. beliefs about illness and medication) are important and are related to adherence to 
treatment in other chronic conditions (Weinman and Petrie, 1997).
The Self-Regulatory Model
A number of models have been proposed to explain how psychological factors influence 
adherence. One model that has proved popular with researchers is Leventhal and colleagues’ 
self-regulatory model (SRM), as it can be applied to a wide range of specific illness conditions 
(Leventhal et al. 1980; Leventhal et al. 1992). Cognitive and emotional representations of the 
illness (‘illness perceptions’) are of key importance in the SRM. It is proposed that illness 
perceptions influence coping behaviours, including adherence to treatment regimens, and 
health outcomes in people experiencing illness. The SRM is a dynamic system and it is 
proposed that coping effectiveness is reappraised, impacting on cognitive and emotional 
representations, and future coping responses.
Evidence Supporting the Application o f the SRM to Adherence
A meta-analysis of forty-five studies using the SRM indicated that there was a reliable 
empirical basis for the proposed relationships between illness perceptions, coping and 
outcomes (Hagger & Orbell, 2003). Illness perceptions are proposed to be structured around 5 
dimensions -  that is the identity, timeline, consequences, causal factors and control/curability 
of the illness. Hagger and Orbell looked at the relationship between these dimensions and 
illness outcomes in their review and concluded that a chronic timeline, more serious 
consequences, a strong illness identity and a high number of symptoms were associated with 
poorer adjustment and outcomes, whereas a higher perceived level of controllability/curability 
was associated with better adjustment.
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Most papers use the Illness Perceptions Questionnaire (Weinman et al. 1996) to measure 
cognitive representations. Studies have more recently used the revised version of this scale to 
measure emotional representations as well as the cognitive dimensions described above, 
enabling a comprehensive assessment of the SRM (Moss-Morris et al. 2002). Such studies 
indicated that higher emotional reactions were linked to poorer adherence (Ross et al. 2004) 
and reduced quality of life (Fowler & Baas, 2006).
The SRM has been used to explore adherence to treatment in diverse chronic illness 
populations and there is good evidence that the dimensions are stable across illnesses. 
However, Hagger and Orbell (2003) highlighted that the pattern of beliefs varies across 
illnesses and ought to be explored for different illness groups. There is a paucity of research 
examining illness perception variables, and their effects on treatment adherence, in the chronic 
pain literature.
Modelling the SRM
Studies demonstrating the value of the SRM in explaining adherence in chronic illness have 
mostly used regression analyses, which despite being depicted using path diagrams, do not 
allow for formal tests of mediating relationships. Few studies have fully tested the extent to 
which the data fit the predicted relations between illness perceptions and adherence. Home 
and Weinman (2002) used structural equation modelling to examine the direct and indirect 
relationships between illness perceptions and medication beliefs in explaining non-adherence 
to asthma medication. They demonstrated that illness perceptions influence adherence both 
directly and indirectly through medication beliefs i.e. individuals who believed their asthma 
was a passing condition were less likely to support the necessity of their treatment, and were, 
as a consequence, less adherent to it. Figure 1 reproduces their model.
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Insert Figure 1 here
Home and Weinman’s (2002) study suggested that the strength of the SRM to explain 
adherence was improved by extending it to include medication beliefs, and it provided 
preliminary empirical support for an extended self-regulatory model of treatment adherence.
Modelling the SRM in Chronic Pain
Moss-Morris et al. (2002) validated the IPQ-R on a sample of chronic pain patients and found 
that people with chronic pain had stronger perceptions of their illness as chronic, cyclical and 
uncontrollable with serious consequences and a high emotional impact than people with acute 
pain. To date there have been no studies using the SRM to predict adherence to treatment in 
chronic pain, although Gill and de C. Williams (2001) investigated whether illness and 
medication beliefs were related to the willingness of pain patients to try Cannabinoids as a pain 
reliever (Gill & de C.Williams et al. 2001) and Hobro et al. (2004) used the SRM to cluster 
chronic pain patients into subgroups. This study examines the role of illness perceptions and 
medication beliefs in predicting adherence, testing the applicability of the extended self- 
regulatory model for the first time in the chronic pain population.
Hypotheses
1) Adherence to prescribed medication will be explained by illness perceptions as 
described by Hagger and Orbell (2003): Perceptions of a chronic timeline, more serious 
consequences, a strong illness identity, more symptoms and higher emotional response 
will be associated with poorer adherence, and higher perceived levels of 
controllability/curability will be associated with better adherence.
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2) Adherence to prescribed medication will correlate positively with patients’ perceptions 
of the need for prescribed medication and correlate negatively with concerns about 
potential negative effects.
3) Beliefs about medication will add to the proportion of variance in adherence that is 
explained by illness perceptions, clinical factors and demographic variables.
4) The extended SRM model, as proposed in Home and Weinman (2002), will be a good 
fit to the data (as judged by a variety of fit indices).
Study Design
Participants
Participants were adults with non-malignant chronic pain who were prescribed medication for 
pain at hospital-based pain clinics in Glasgow. Participants could understand written and 
spoken English. Pain conditions sampled were heterogeneous.
Recruitment
All patients attending pain clinics in north Glasgow across a four-month period (November 
2005-February 2006) received study information (Appendix 4.2) before clinic attendance and 
could opt-in to the study at their clinic appointment. Participants had the option of completing 
the questionnaires at the clinic or returning them in the SAE provided. Approval was granted 
from the local ethics committees (Glasgow Primary Care and North Glasgow Hospital 
Committees, approval letters Appendix 4.3).
Measures
This study adopted four standardised self-report measures in addition to questions regarding 
relevant demographic and clinical variables (questionnaire pack, Appendix 4.4).
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1) The Illness Perceptions Questionnaire -  Revised, IPQ-R (Moss-Morris et al. 2002).
The IPQ-R was chosen over the original Illness Perceptions Questionnaire (Weinman et al. 
1996) as it has been validated on chronic pain patients and found to have good reliability and 
validity (Cronbach’s alpha’s for each of the subscales range from .79 to .89 and test-retest 
correlations from .46 to .88). The IPQ-R also includes a measure of emotional response to 
illness, enabling evaluation of emotional representations. The IPQ-R includes the 5 original 
dimensions of the SRM but breaks timeline and control beliefs into two scales. Scores for 
eight of the nine scales (identity, timeline, timeline cyclical, consequences, personal control, 
treatment control, coherence and emotional representation) are summed individually to assess 
the relative contributions they make to adherence. The cause section is not treated as a scale 
but analysed as separate items in accordance with authors’ recommendations (Moss-Morris et 
al. 2002).
2) Beliefs about Medicines Questionnaire, BMQ (Horne et al. 1999)
The specific section of the BMQ was employed to measure patients’ beliefs about medication 
prescribed for pain. The BMQ specific section contains two scales: one assessing the patient’s 
concerns about their medication the other their beliefs about the necessity of their medication. 
It has been validated on other chronic illness populations and shows good reliability and 
validity (Ramsay et al. 2006, unpublished thesis).
3) Medication Adherence Report Scale. MARS (Home and Hankins, 2001).
The MARS is a self-report questionnaire that assesses the degree of adherence to prescribed 
medications (Home and Weinman, 2002) The frequency of 5 non-adherent behaviours 
(deciding to miss a dose, forgetting to take a dose, altering the dose, stopping taking doses for a 
while and taking less than instmcted) is measured on a 5-point Likert-type scale. A sixth item
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( ‘I take more than instructed’) was added following discussion with the authors to capture an 
additional element of non-adherence relevant to the pain population. Scores were summed to 
give a continuous measure of adherence. Convergent validity has been assessed between the 
BMQ and MARS with negative correlations between the BMQ-concerns and MARS and 
positive correlations between BMQ-necessity and MARS (Home and Hankins, 2001).
There are limitations to using a self-report measure of adherence, however, due to practical 
reasons, it was the only clinically viable option in this study. Self-report has been found to 
differ from objective measures of adherence by around 30% in chronic pain patients (Bemdt et 
al. 1993). Whilst toxicology screening would provide the most accurate way of measuring 
adherence, self-report is recognised as an acceptable estimate of adherence when objective 
measures are ethically inappropriate, or not viable for practical reasons (Stephenson, 2003).
4) Pain Numerical Rating Scale. PNRS
Numerical rating scales have been recommended to measure pain in chronic pain trials by a 
leading international group of pain researchers (McQuay, 2005). The PNRS provides a 
measure of the severity of the patient’s pain by asking them to rate their pain on a scale of 0 to 
10, where ten indicates the most severe pain.
Power Calculation
A formal calculation of sample size indicated that 216 patients were required for the study to 
be adequately powered (UCLA website). This is based on a Null hypothesis value of 0, an 
alternative hypothesis value of .19 (using the weakest correlation coefficient from Home and 
Weinman, 2002), and using conventional significance levels of .05, a power of .8 and a 2-tailed 
design. However, the sample size required is reduced to 171 using the one-tailed design used 
here.
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Statistical Methods
Statistical analysis was carried out using the SPSS for Windows statistical software Package 
(version 13, SPSS Inc. 2004). The reliability and distribution of scales was checked before 
performing bivariate and multivariate analyses. Pearson correlation coefficients were 
employed to examine the relationship between demographic, clinical, illness perceptions and 
medication belief variables with adherence. Hierarchical linear regression was then used to 
identify the variables predicting adherence, using only variables identified as significant at the 
bivariate level. This methodology is often used when there are a large number of variables 
measured and is a procedure used in similar study designs (e.g. Butler et al. 2004, Ross et al. 
2004). The extended SRM model proposed in a previous chronic illness sample (Home and 
Weinman, 2002) was tested using Structural Equation Modelling analysis (statistical package 
EQS, version 6.1: Bentler, 1995). This approach also allows the overall fit of the model to be 
evaluated as well as testing the significance of mediated pathways between elements of the 
model.
Results
The results will be presented in the following order: firstly, missing data procedure,
demographic details, scale descriptives and the relationships between demographic variables 
and adherence are described. Findings relating to the study hypotheses are then addressed 
directly.
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Missing data
Questionnaires were rejected if more than 30% of items were missing or illegible (following 
the methodology of Horne et al. 2001). Eighteen percent of questionnaires were rejected. 
Missing data on the IPQ-R were addressed using the mean imputation method advised by the 
scale developers (see website for scoring details: www.uib.no/ipq). The same procedure was 
adopted for the BMQ and MARS scales.
Participants
The demographic and clinical characteristics of 217 participants are presented in Table 1. The 
participants represent a broad range of age and education, although it is worth noting that they 
represent inner city clinics and around one third of participants left school without formal 
qualifications. Participants had been experiencing pain for a mean of 10 years but this ranged 
from 6 months to 42 years. Pain ratings were high with an average of 8 out of 10. Two thirds 
of participants rated more than one location of pain. The lower back was the most common 
site of pain (44%), followed by legs (22%) and neck (12%). Participants were taking a very 
wide range of medicines with 51 different brands reported. The most common type of 
medication taken was Tramadol, a moderately strong, opiate-based analgesic (28%).
Ethics recommendations precluded access to details of non-respondents, but participants were 
compared with the demographics of an audit of new patients attending Glasgow pain clinics 
(Rae et al. 1999). Participants did not differ in terms of age, gender or location of pain. 
However, despite the poor education status of participants in this study, twice as many (62%) 
of participants in the audit left school without formal qualifications. There are therefore a 
considerable proportion of clinic attendees that may have literacy problems. The impact of 
education on adherence is further investigated below.
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Insert Table 1 here
Scale Descriptives
The internal consistency and distribution of scales were checked before performing bivariate 
and multivariate analyses (see Table 2). Internal consistency (as measured by Cronbach’s 
alpha) was acceptable for all scales except IPQ-R personal control (0.66), IPQ-R treatment 
control (0.65) and BMQ concerns scales (0.62), which were borderline. Scales were normally 
distributed except the MARS scale, which was positively skewed (skewness statistic 1.520, SE 
1.74). It was therefore transformed before being entered into analyses.
Insert Table 2 here
Illness Perceptions Scales
The means for scales and percentage of participants scoring above the scale mid-point 
(participants agreeing or strongly agreeing with statements) are given in Table 2. Most people 
saw their pain as a chronic (84%), and a cyclical (55%) condition. Participants reported that 
their pain had serious consequences on their life (72%). Only 36% reported that they felt in 
control of their pain and had confidence in the efficacy of medication in controlling their pain. 
Over half the sample (58%) reported a strong emotional response to their pain.
The IPQ-R Cause subscale was not treated as a cohesive scale in line with authors’ 
recommendations and items were looked at individually. Participants most commonly rated 
‘bad luck’ (42% sample agreeing or strongly agreeing with this as a causal agent), an accident 
(41%), aging (33%), or emotional state e.g. feeling down, lonely, anxious (28%) as related to 
their illness. However, there was a wide range of causal attributions endorsed by participants. 
The relationship between these four causal attributions and adherence was investigated
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(applying the methodology of Home and Weinman, 2002) using Independent sample t-tests. 
None of the four causal beliefs were significantly related to adherence and this scale was 
therefore dropped from further analysis.
Beliefs about Medicines
Sixty four percent of participants agreed or strongly agreed that their medicines were 
necessary, 42% agreed or strongly agreed that they had concerns about their medicines and 
22% held both necessity and concern beliefs about medication.
MARS
As mentioned above, scores on the MARS were positively skewed (mean 1.69, SD 0.71). 
Twenty five percent of participants scored over the mid-point on the scale. The percentages of 
the sample endorsing individual MARS items are described in Table 3.
Insert Table 3 here
Relationships between demographic and clinical variables and adherence 
Pearson correlation coefficients between study variables and adherence are shown in Table 4. 
Age was highly significantly correlated with adherence (r = -.24, p<0.01) indicating that older 
participants were more adherent to their pain medication than were younger participants. 
Participants with more education were also more adherent (r = .12, p<0.05). Gender was not 
significantly associated with adherence. The participants ratings of the severity of their pain 
was the only significant variable out of the clinical variables (r = -.22, p<0.01) indicating that 
those with greater pain were more adherent to their medication.
Insert Table 4 here
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Testing the study hypotheses
Hypothesis 1. Adherence to prescribed medication will be explained by illness perceptions as 
described by Hagger and Orbell (2003): with perceptions o f a chronic timeline, more serious 
consequences, a strong illness identity, more symptoms and higher emotional response being 
associated with poorer adherence, and higher perceived levels o f controllability/curability 
being associated with better adherence.
Pearson correlation coefficients between IPQ-R scales and reported adherence are displayed in 
Table 4. Higher scores on the timeline cyclical subscale (r = .16, p<0.05) were associated with 
poorer adherence, as hypothesised. Perception of a chronic timeline (r = -.13, p<0.05) was 
associated with greater adherence. Higher perceived levels of control were associated with 
poorer adherence (r = .15, p<0.05). The findings for the timeline and control subscales differ 
from the hypothesised direction of the relationships. Consequences, illness identity, treatment 
control, illness coherence and emotional subscales were not significantly associated with 
adherence. Hypothesis 1 was therefore only partially supported as some IPQ-R subscales were 
not significantly related to adherence, and not all associations were in the predicted direction.
The IPQ-R subscales that were not related directly to adherence were significantly related to 
the BMQ scales, except treatment control. Increased identity (r = .19, p<0.01), consequences 
(r = .24, p<0.01) and emotion (r = .31, p<0.01) scores were highly correlated with increased 
concerns about pain medications whereas increased illness coherence was significantly 
associated with fewer concerns (r = -.21, p<0.01). Increased consequences (r = .47, p<0.01), 
timeline (r = .28, p<0.01) and emotion (r = .32, p<0.01) scores were highly significantly 
correlated with increased treatment necessity, whereas increased personal control was 
associated with lower necessity scores (r = -.12, p<0.05).
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Hypothesis 2. Adherence to prescribed medication will be related to beliefs about medication. 
Adherence will be positively correlated with patients’ perceptions o f  the necessity o f  
prescribed medication and negatively correlated with concerns about potential negative 
effects.
Table 4 also illustrates that necessity was highly significantly correlated with adherence (r = - 
.19, p<0.01) with those who held higher necessity beliefs being more adherent. Concerns were 
significantly correlated with adherence, indicating that those with higher concerns were less 
adherent to their medication (r = .12, p<0.05). Hypothesis 2 is supported but it is acknowledged 
that these correlations are low and the large sample size of this study, combined with multiple 
comparisons, increases the chance of type 1 error.
Hypothesis 3: Beliefs about medication will add to the proportion o f  variance in adherence 
that is explained by illness perceptions, clinical factors and demographic variables.
A hierarchical linear regression (Table 5) demonstrated that 5% of the variance in adherence 
scores was explained by the demographic variables ‘age’ and ‘educational status’. A further 
2% of the variance was explained by considering the clinical variable ‘pain rating’. Illness 
perceptions (timeline, timeline cyclical and personal control) and beliefs about medicines 
(necessity, concerns) each add a further 3% to the variance explained. Hypothesis 3 is 
supported, as beliefs about medication add to the proportion of the variance explained by 
illness perceptions, clinical factors and demographic variables. However the amount of added 
variance is small and the overall the regression model explains only 9% of the variance. 
Regression analysis did not provide strong evidence that illness and medication beliefs explain 
variance in adherence. Structural equation modelling provided a stronger explanatory model 
and this is outlined below.
Insert Table 5 here
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Hypothesis 4: Structural Equation Modelling -  The extended SRM model, as proposed in 
Horne and Weinman (2002), will be a good fit  to the data (as judged by a variety offit indices). 
The model proposed by Home and Weinman (2002) was tested (see Figure 1), but it was not 
confirmed as a good fit for the current data (CFI = 0.78, RMSEA = 1.45, x2 = 21 A l, d.f. = 4, p 
= 0.00002). Appendix 4.5 provides further information on calculating goodness-of-fit in 
structural equation modelling. This model indicated that consequences were highly predictive 
of necessity scores and timeline was not related to the other variables. A modified model using 
the same variables without the timeline subscale was therefore tested, but did not fit the data 
(CFI = 0.79, RMSEA = 0.184, - /  = 21.75, d.f. = 3, p = 0.00007). These models were 
conducted on the basis of past empirical results but were not representative of this population. 
An alternative model was proposed after revisiting the correlation coefficient matrix. The IPQ- 
R emotional representation and consequences scales had the largest relationships at the 
bivariate level with BMQ scales. The emotional representation scale was not included in 
Home and Weinman’s (2002) analysis and so its role in predicting adherence had not been 
tested. It was therefore theorised that emotion, as well as perceived consequences of pain, 
played an important role in affecting the treatment beliefs of this pain population.
A model including the IPQ-R scales of emotion and consequences and the BMQ scales of 
necessity and concerns was a good fit for the data (CFI = 0.974, RMSEA = 0.058, Satorra 
Bentler Scaled x2 = 8.15, d.f. = 5, p = 0.15). The model is presented in Figure 2. To 
summarise this model, the IPQ-R scales influence adherence indirectly through medication 
beliefs. Higher consequence scores are associated with increased emotion, necessity and 
concern scores. Increased emotion is associated with increased concerns scores. Higher 
necessity scores predict better adherence while higher concerns score predict non-adherence. 
This model provides support that an extended SRM can be applied to chronic pain populations.
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It is similar to the model proposed by Home and Weinman (2002) as medication beliefs 
directly influence adherence whereas illness perceptions indirectly affect adherence. However, 
the significant illness beliefs differ in this population from those found in their asthma sample. 
Hypothesis 4 is therefore supported, although with some modification regarding the specific 
illness perceptions that influence adherence in this chronic pain population.
Insert Figure 2 here
Discussion
Study results
The main aim of this study was to examine the roles of illness and medication beliefs in 
reported adherence to medication prescribed for chronic pain. The study hypotheses were 
largely upheld. Illness and medication beliefs were related to adherence at the bivariate level, 
added to the variance explained in a regression analysis, and a structural equation model that 
included these variables was found to be a good fit to the data. The results relating to each 
hypothesis will be discussed before the study limitations and practical implications are 
examined.
Illness Perceptions and adherence
Participants viewed their pain as having a chronic, cyclical, uncontrollable course with serious 
consequences and a high emotional impact. This pattern of beliefs is consistent with the beliefs 
of chronic pain patients described by Moss-Morris et al. (2002). Hypothesis 1 was not fully 
confirmed, as although some illness perceptions were significantly related to adherence, others 
were not in the predicted direction or were non-significant. It is not surprising that the overall 
pattern of relationships differs from those described by Hagger and Orbell (2003), as studies of
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different illness populations have found variations in patterns of illness perceptions (e.g. Ross 
et al. 2004). Indeed, although Hagger and Orbell (2003) conclude that illness representations 
are consistent in terms of dimensions across illnesses, they assert that significant differences 
remain between illness groups depending on severity, chronicity and illness type. This study is 
the first to describe the pattern of relationships between illness perceptions and adherence in 
chronic pain. Perceptions of a chronic, uncontrollable and unremitting (not cyclical) illness 
were associated with greater adherence to pain medications at the bivariate level.
It is interesting that illness perceptions that were not significantly associated with reported 
adherence were, with the exception of treatment control, related to medication beliefs. This 
finding is consistent with other papers that propose that the impact of the IPQ variables on 
adherence is mediated through the BMQ (Home and Weinman, 2002, Ross et al. 2004). One 
might speculate that the treatment control scale would be associated with medication beliefs, 
however it was not in this study, suggesting that this scale may be measuring a different 
construct.
Beliefs about medicines and adherence
Two thirds of this sample believed their medicine was necessary, yet 42% also held concerns 
about their medication. It has been suggested that people weigh up their relative medication 
beliefs and are adherent if the necessity of their medicine is perceived more strongly than their 
concerns (Home and Weinman, 1999). It is therefore possible for individuals to hold concerns 
about their medication and still be adherent. However, this study found that people who report 
stronger concerns and doubts about the necessity of their medication were more likely to have 
problems with adherence. This finding fits with the relationships between beliefs about 
medicines and adherence described in the other chronic illness samples (Ramsay et al. 2006, 
unpublished thesis).
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Medication beliefs will add to the variance in adherence explained by other variables 
Although illness and medication beliefs added to the amount of variance in adherence 
explained overall, the total amount of variance explained by psychological variables was less 
than expected given the findings of other studies. Home and Weinman (2002) found 
medication beliefs explained 17% more variance than illness perception, demographic and 
clinical variables alone. The considerably weaker effect found in this study could be 
attributable to making only a minor adjustment to the MARS scale and not tailoring the other 
scales to be more specific to this population. It could also be a consequence of the larger 
impact of the demographic variables found in this study, or, and perhaps most likely, it could 
be due to the differences between this population and other chronic health conditions.
Home and Weinman (2002) added seven asthma specific items to the BMQ and four to the 
MARS. Although this study added one item to the MARS (T take more than instructed’), 
adding further items specific to chronic pain may have increased the variance explained by 
these measures. However, adding too many items may ‘conflate’ results and undermine 
confidence in the reliability and validity of these scales. Furthermore, there is a great deal of 
heterogeneity in the types of medicine taken for pain, which varies from analgesics to anti­
epileptics. Therefore, it is difficult to make simple adjustments to the measures of medication 
beliefs so that they tie in with all the medicines used in the chronic pain population. Home and 
Weinman (2002), on the other hand, could specify questions relating to the two main types of 
asthma medicines (preventer and reliever inhalers).
The results of this study suggest that age has an important relationship with adherence in 
chronic pain and this is surprising given that other studies, such as Home and Weinman (2002), 
have found that demographic variables have a negligible association with adherence. A
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significant relationship between age and adherence has been often observed in chronic illness 
samples (see Ramsay et al. 2006, unpublished thesis for a review). The interaction between 
age and adherence is well explained by the SRM, as it is inherent in self-regulatory theory that 
illness representations change over time. Leventhal and Crouch (1997) discuss the manner in 
which illness representations change across the lifecourse. It is suggested that older age is 
associated with overestimating chronicity, morbidity and mortality and therefore has the effect 
of increasing treatment seeking and compliance.
An extended self-regulatory model will be a good fit  to the data
The structural equation model describes the ways in which patients’ models of illness 
perceptions and treatment beliefs relate to adherence. Patients were more likely to have 
concerns about their medication if they believed that chronic pain had serious consequences 
and they were experiencing a greater emotional response to their illness. The consequence 
scale has been shown to be related both to expressing emotions and to avoidance coping 
strategies in other studies (Hagger and Orbell, 2003). It is perhaps unsurprising that people 
who are anxious will worry more about the effects of their medicines, what is more unexpected 
is the dual relationship between adherence and consequences i.e. people who experience 
serious consequences are also more likely to hold beliefs about the necessity of their 
medicines.
These results may indicate the appraisal process inherent in the self-regulatory model. For 
some people experiencing serious consequences, beliefs in the necessity of medication will 
outweigh concerns, resulting in better adherence. For others, concerns will outweigh necessity. 
Home and Weinman (2002) suggest that illness consequences may be the result of adherence 
behaviour rather than a determinant and highlight the need for prospective studies to determine 
the causal direction of these effects. This model confirms a direct relationship between
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necessity and concerns and adherence. This study therefore adds to the growing literature 
providing support for an extended self-regulatory model that includes beliefs about medicines 
as well as illness perceptions (Home and Weinman, 2002; Byme et al, 2005, Ross et al, 2005).
Limitations
It is important to acknowledge that the SEM model depicted in this study was derived from a 
post hoc analysis after the replication of a model that was a good fit in an asthma population 
did not fit this pain population. This study used the revised version of the Illness Perceptions 
Questionnaire and therefore had illness belief variables available for inclusion that were 
unavailable in Home and Weinman’s study (2002). They, particularly, were unable to measure 
the emotional representations of illness that proved important in this study population. 
Nonetheless, the model proposed here requires replication to determine the reliability of these 
results.
This study has a number of other limitations. Firstly, the cross-sectional design prevents 
exploration of the direction of causality. This would have been interesting, given that the 
pattern of associations between illness perceptions and adherence differed from those expected. 
Secondly, it may have been limited by measuring adherence through self-report. This study 
did not have the resources to use toxicology screening, which can be regarded as the gold 
standard. Self-report is less accurate than objective measures of adherence, but it has been 
shown to be a useful way to measure adherence when objective measures are unavailable (e.g. 
Choo et al. 1999, Dimtteo et al. 2002). Furthermore, it is the most practical and inexpensive 
measure to use in everyday practice.
Another consideration, regarding the reliability and validity of these results, is the poor 
educational status of many of the participants taking part in the study. It is possible that
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question wording effects or simple literacy problems influenced the responses of this sample. 
Poor literacy may also have influenced the participants’ adherence through increasing 
involuntary non-adherence i.e. through not understanding written dosage instructions. There is 
evidence that low levels of education are very common in pain clinic populations and it is 
therefore important to consider this in practice or when designing further research. Around one 
third (35%) of participants had no formal qualifications; this is less than a previous audit of 
Glasgow pain clinics, but similar to those described in another study investigating the SRM in 
a UK pain clinic sample (Hobro et al. 2004).
Practical Applications
This study is the first to explore the specific illness and medication representations that most 
strongly affect adherence in the chronic pain population. The direct cost of back pain is 
estimated to be £1632 million in the UK (Maniadakis and Gray, 2000). In financial terms 
alone, there is an obvious need to develop services that manage chronic pain more efficiently. 
A systematic review of outpatient services for chronic pain concluded that, while there is 
evidence that chronic pain clinics use interventions that provide pain relief for patients, there is 
little known about why treatment does not work for some (McQuay et al, 1997). It is 
acknowledged that problems with adherence are reducing the efficacy of pain treatments and 
that improving adherence will improve pain control within this population.
Despite the above limitations, the results of this study can be used to improve practice by 
providing a model for understanding non-adherence. Firstly, this study demonstrates that 
medication beliefs have a salient and direct effect on chronic pain patients’ adherence. On an 
individual basis, clinicians could therefore use the BMQ to detect problematic medication 
beliefs in patients with poor adherence and then challenge these beliefs through discussion with 
the patient. A more global and less specific approach could be designing an information sheet
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that highlights the necessity and discusses the concerns, e.g. side effects that patients may hold 
about pain medication. However, it is worth considering the low levels of education in clinic 
patients when designing any written information. The efficacy of both these approaches could 
be evaluated in future studies. Secondly, challenging the illness representations that influence 
medication beliefs may also enhance the impact of interventions. For example, highlighting 
the relationship between good adherence and fewer consequences of pain (e.g. better able to 
perform activities of daily living) may increase the perceived need for medicines and improve 
adherence.
It would be interesting to further explore the role that emotion has on coping strategies in 
chronic pain by including a comprehensive measure of anxiety and depression in a longitudinal 
study. There are many ways in which mood may affect illness representations and adherence. 
Increased levels of anxiety can inflate concerns about medication as found in this study. Stress 
management skills may reduce emotional response and prove helpful in improving adherence 
in chronic pain patients by reducing their treatment concerns. However, mood could also 
affect adherence through other routes that are not as well represented by the emotions scale of 
the IPQ-R e.g. depression could increase pessimism regarding treatment effectiveness. Indeed a 
recent study found that patients with coronary heart disease that were depressed were less 
adherent than those that were not depressed (Bane et al. 2006). Levels of depression and their 
impact on adherence in chronic pain should be assessed in future studies.
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Figure 1 A Structural Equation Model of the extended SRM (Horne and 
Weinman, 2002)2
Treatment
concerns
treatment
necessity
Illness
timeline
reported
adherence
Illness
consequences
2 el and e2 indicate error values in the model.
Table 1 Demographic information and illness features (N = 217)
Gender (% female) 65
Age
Mean (SD) 50.6(14.1)
Range 19-86
Education: (%)
No Formal Qualifications 35
Secondary 30
Tertiary 25
Higher 10
Duration of pain (years)
Mean (SD) 9.5 (8.5)
Range 0.5-42
Pain rating
Mean (SD) 8 (6.5)
Most frequent locations of pain (%) lower back (4'
legs (22)
neck (12)
Patients rating >1 location (%) 66
No of pain medications
Mean (SD) 2.8 (1.8)
Range 1-10
Type of Pain Medication Tramadol
(5 most common) Amitriptyline
Paracetamol
Gabapentin
Co-codamol
Table 2 Scale Descriptives
Scale No. items 
in Scale
Cronbach’s 
Alpha (N*)
Mean SD Scores over 
mid-point (%)
IPQ-R Identity 14 NA 5.15 3.41 NA
IPQ-R Timeline 6 0.81 (185) 4.1 0.69 84
IPQ-R Consequences 6 0.79(199) 3.91 0.79 72
IPQ-R Timeline cycle 4 0.74 (205) 3.24 0.94 55
IPQ-R Personal Control 6 0.66(199) 2.94 0.70 36
IPQ-R treatment control 5 0.65 (200) 2.94 0.64 36
IPQ-R coherence 5 0.89 (203) 3.1 1.04 47
IPQ-R Emotion 6 0.83 (203) 3.62 0.84 58
IPQ-R Cause 17 NA NA NA NA
BMQ necessity 5 0.85 (209) 3.81 0.9 64
BMQ concerns 5 0.62 (208) 3.28 0.83 42
MARS 6 0.78 (195) 1.69 0.71 25
* Numbers vary as individual scales may have been missing for some participants.
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Table 3 Responses to items on the Medication Adherence Report Scale (MARS)
Type of non-adherence to 
pain medication
% Sample admitting type of non­
adherence (sometimes, often, always)
I forget to take them 19
I alter the dose 34
I stop taking them for a while 21
I decide to miss a dose 26
I take less than instructed 24
I take more than instructed 26
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Table 5 Hierarchical linear regression model of predictors of reported 
adherence to pain medicines
P r e d ic to r  B lo c k V a r ia b le s  e n te r e d  r P A d ju s te d  R 2 I n c r e a s e  in  R 2
Demographic variables 0 .0 4 0 .05
F (2 ,1 7 6 )  =  4 .9 6 , p =  0 .0 0 8 A g e -.2 2 2 * *
E d u cation al Status .0 2 8
Clinical Factors 0 .0 6 0 .0 2
F (3 ,1 7 5 )  =  4 .7 7 , p =  0 .0 0 3 A g e .2 1 4 * *
E d u cation a l Status .0 0 0
P ain  rating - .1 5 2 *
Illness perceptions 0 .0 7 0 .0 3
F (7 ,1 7 1 )  =  2 .9 9 , p =  0 .05 A g e - .1 7 3 *
E d u cation a l Status - .0 0 4
Pain rating - .1 1 6
T im e lin e -.0 9 2
P ersonal control .065
T im e lin e  C y c lica l .0 8 8
Treatment beliefs 0 .0 9 0 .0 3
F (9 ,1 6 9 )  =  2 .9 1 , p =  0 .0 0 3 A g e ,24** -.141
E d u cation al Status 12* .0 2 7
Pain rating 2 2 * * -.0 9 8
T im e lin e .13* - .0 5 7
P ersonal control 15* .0 5 7
T im e lin e  C yc lica l .16* .0 7 8
N e c e s s ity .19** - .1 3 0
C on cern s 12* .1 5 7 *
S ig n if ic a n c e  P < .0 5 *  
p <  01 ** (o n e  ta iled )
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Abstract
Background: Cognitive Behavioural Therapy (CBT) for Chronic Fatigue Syndrome highlights 
the interplay between activity, beliefs, mood and fatigue and is the psychological treatment of 
choice for this illness. However, there is debate whether it is the behavioural or cognitive 
components that are most significant in alleviating symptoms.
Design and analysis: This case assesses the relative contributions of behavioural and
cognitive components of CBT in improving sleep, activity, depression, illness cognitions and 
fatigue, using an ABC design with repeated measures. Data were analysed using visual 
inspection and time series analysis.
Results: The behavioural phase impacted on time of sleep onset at a statistically significant 
level. Activity, depression and two illness beliefs (‘My symptoms are out of my control’ and 
‘if I can’t do my work at a 100% level then I can’t do it at all’) improved at a clinically 
significant level. Another illness belief (‘I am to blame for my symptoms’) and fatigue were 
not affected by the behavioural phase. Illness cognitions did not prevent behavioural 
treatment impacting on outcome variables, but further change was seen in all variables except 
fatigue following the cognitive phase. Overall, there were clinically significant changes in 
sleep onset, activity, depression and beliefs by end of treatment. Subjective experience of 
fatigue did not change.
Discussion: The findings highlight the potential of single case methodology to investigate the 
process of change in therapy. In this study the behavioural components of therapy resulted in 
quick clinical change and improved engagement in therapy. Additional cognitive work 
strengthened and stabilised the change. Further research could investigate this finding using 
more generalisable methodology. Study limitations are discussed.
Key words: Chronic Fatigue Syndrome; cognitive behavioural therapy; process
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Appendix 1.1 Guidelines for Submitting to Clinical Psychology
Guidelines for Submitting to Clinical Psychology
• Articles of 1000-2000 words are welcomed. Send two hard copies of your 
contribution.
• When sending copy, make sure it is double spaced, in a reasonably sized font and 
that all pages are numbered.
• Give a 40-word summary at the beginning of the paper.
• Contributors are asked to use language which is psychologically descriptive rather 
than medical and to avoid using devaluing terminology; i.e. avoid clustering 
terminology like ‘the elderly’ or medical jargon like ‘person with schizophrenia’. 
If you find yourself using quotation marks around words with dubious meaning, 
please use a different word.
• Articles submitted to Clinical Psychology will be sent to members of the Editorial 
Collective for refereeing. They will then communicate directly with the authors.
• We reserve the right to shorten, amend and hold back copy if needed.
• Include a word count at the end (including references).
• Spell out all acronyms the first time they appear.
• Include the first names of all authors and give their employers, and remember to 
give a full postal address for correspondence.
• Give references in Clinical Psychology style, and if a reference is cited in the text 
make sure it is in the list at the end.
• Don’t include tables and figures unless they save space or add to the article.
• Ask readers to request a copy of your questionnaire from you rather than include 
the whole of it in the article.
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Appendix 1.2 Action Plan Arising from Project
Action Plan
July
• Presentation at team meeting to update on findings of study. Preliminary findings 
discussed at June meeting (LR)
• Commence screening of anger referrals on waiting lists of all 3 sub-sectors for 
Anger Management group (RS)
• Contact Forensic Clinical Psychologist to arrange teaching session (LR)
August
• Possible presentation by forensic clinical psychologist on how to manage anger
referrals (FS)
• Liasing with Community Mental Health Team in the Mid-sector regarding
appropriate referrals to clinical psychology (JP).
September
• Screen suitable referrals for next Stress Management group (JD)
• Possible start of Anger Management group (RS)
January 2005
• Repeat audit of number of anger referrals for comparison with present numbers 
(AJ)
• Evaluate Anger Management group (RS)
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Appendix 2.1 Guidelines for Submitting to Psychology and Health 
PSYCHOLOGY AND HEALTH: INSTRUCTIONS FOR AUTHORS
INTRODUCTION
Submission of a paper to Psychology & Health will be taken to imply that it represents original work not previously 
published, that it is not being considered elsewhere for publication, and that if accepted for publication it will not 
be published elsewhere in the same form, in any language, without the consent of editor and publisher. It is a 
condition of the acceptance by the editor of a typescript for publication that the publisher automatically acquires 
the copyright of the typescript throughout the world.
SUBMISSION OF MANUSCRIPTS
One hard copy of each manuscript, and an electronic version, should be sent to Paul Norman, Department of 
Psychology, University of Sheffield, Sheffield, S10 2TP, UK. Each paper will be read by at least two referees.
FORMAT OF MANUSCRIPTS
Manuscripts should be typed according to the guidelines in the Publication Manual of the American Psychological 
Association (4th edition, 1994); however, please follow the present Instructions for Authors in cases of
contradiction with the APA guidelines. Manuscripts should not exceed 30 pages (including references, tables,
figures, etc).
Title page: This should contain the title of the paper, a short running title, the name and full postal 
address of each author and an indication of which author will be responsible for correspondence, reprints 
and proofs. Abbreviations in the title should be avoided.
Abstract: This should not exceed 150 words and should be presented on a separate sheet,
summarizing the significant coverage and findings.
Key words: Abstracts should be accompanied by up to six key words or phrases that between them 
characterize the contents of the paper. These will be used for indexing and data retrieval purposes.
TEXT HEADINGS
All headings in the text should be set over to the left-hand margin, and the text should begin on the next line. Type 
first level (sectional) headings all in capitals. For second and third level headings, only the first letter of the first 
word should be a capital. Underline third level headings. For example:
FIRST LEVEL TEXT HEADINGS
Second Level Text Headings
Third level text headings
REFERENCES
References should be indicated in the text with the author's name and year of publication in parentheses. If there 
are two authors, both names should be given. If there are more than two authors, all should be given on the first 
occasion, and then the first author "et al." should be used subsequently. Use "and" between author names 
mentioned in the text and an ampersand (&) when mentioned in parentheses and in the reference section. The 
full list of references should be given in alphabetical order on a separate sheet, with titles of books and journals 
given in full. Generally, the APA guidelines should be followed for the references. Examples:
1. Johnston, M. (1984) Dimensions of recovery from surgery. International Review of Applied 
Psychology, 33(4), 505-520.
2. Smith, A.P., Tyrrell, D.A.J., Coyle, K.B., Higgins, P.G. and Willman, J.J. (1990) Individual differences 
in susceptibility to infection and illness following respiratory virus challenge. Psychology and Health, 4, 
201 -211 .
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FIGURES
All figures should be numbered with consecutive arabic numerals, have descriptive captions and be mentioned in 
the text. Figures should be kept separate from the text but an approximate position for each should be indicated in 
the margin. It is the author's responsibility to obtain permission for any reproduction from other sources.
Preparation: Figures must be of a high enough standard for direct reproduction. They should be prepared in black 
(india) ink on white card or tracing paper, with all the lettering and symbols included. Axes of graphs should be 
properly labelled and appropriate units given. Photographs intended for halftone reproduction must be high quality 
glossy originals of maximum contrast. Redrawing or retouching of unsuitable figures will be charged to authors.
Size: Figures should be planned so that they reduce to 10.5 cm column width. The preferred width of 
submitted drawings is 16-21 cm, with capital lettering 4 mm high, for reduction by one-half. Photographs 
for halftone reproduction should be approximately twice the desired size.
Captions: A list of figure captions should be typed on a separate sheet and included in the typescript.
TABLES
Tables should be clearly typed with double spacing. Number tables with consecutive arabic numerals and give 
each a clear descriptive heading. Avoid the use of vertical rules in tables. Table footnotes should be typed below 
the table, designated by superior lower-case letters.
PROOFS
Authors will receive proofs (including figures) by air mail for correction, which must be returned within 48 hours of 
receipt. Authors' alterations in excess of 10% of the original composition cost will be charged to authors.
Early Electronic Offprints:
Corresponding authors can now receive their article by e-mail as a complete PDF. This allows the author to print 
up to 50 copies, free of charge, and disseminate them to colleagues. In many cases this facility will be available 
up to two weeks prior to publication. Or, alternatively, corresponding authors will receive the traditional 50 
offprints. A copy of the journal will be sent by post to all corresponding authors after publication. Additional copies 
of the journal can be purchased at the author's preferential rate of £15.00/$25.00 per copy.
REPRINTS
Twenty-five reprints per article will be sent to the senior author free of charge. Additional copies may be 
purchased when returning proofs.
PAGE CHARGES
There are no page charges to individuals or to institutions.
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Appendix 2.2 The Beliefs about Medicines Questionnaire
Beliefs about Medicines Questionnaire
Rated: strongly agree, agree, uncertain, disagree, strongly disagree
Specific Section 
Necessity
My health, at present, depends on my pain medications.
My life would be impossible without my pain medicines.
Without my pain medicines I would be very ill.
My health, in the future, depends on my pain medicines.
My pain medicines protect me from becoming worse.
Concerns
Haying to take pain medicines worries me.
I sometimes worry about the long-term effects of my pain medicines.
My pain medicines are a mystery to me.
My pain medicines disrupt my life.
I sometimes worry about being too dependent on my pain medicines.
General Section 
Overuse
Doctors use too many medicines.
Doctors place too much trust on medicines.
If doctors had more time with patients they would prescribe fewer medicines.
Natural remedies are safer than medicines.
Harms
Most medicines are addictive.
All medicines are poisons.
Most medicines are addictive.
People who take medicines should stop their treatment for a while every now and again.
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Appendix 2.3 Quality Evaluation Criteria
Quality Evaluation Criteria
Study Score
Study title
W hat is the outcome of interest?
1) Objectives
Was the research question clearly stated? Yes-1 No-0
2) Selection of subjects
Was the population defined? Yes-1 No-0
Were the sample demographics stated? Yes-1 no-0
Were all inclusion /exclusion criteria stated? Yes-1 no-0
Was the sample representative? Yes-1 no-0
Was sample size justified? (Power Calculation mentioned) Yes-1 No-0
3) Assessment
What measures used?
Was the BMQ used in a reliable and valid way? Yes-1 No-0
Was adherence measured; Self-report -  1 
Objective measure -  2
Were other outcomes measured in a standard, valid and reliable way? Yes-2, Some-1 No-0
4) Design
Is the study design relevant to the question? Yes-1 No-0
5) Statisical Analysis
Was the data screening (e.g. abnormal distributions) described? Yes-1 No-0
Were appropriate statistical methods applied? Yes-1 No-0
Were all subjects used in analysis? Yes-1 No-0
Was the analysis o f missing data reported? Yes-1 No-0
6) Results
Were appropriate summary measures reported? Yes-1 No-0
Were the results clearly stated? Yes-1 No-0
7) Discussion
Were conclusions supported by data? Yes-1 No-0
Did they consider/explain bias? Yes-1 No-0
Did they consider alternative reasons for results? Yes-1 No-0
Are the data supported by other research? Yes-1 No-0
8) Overall assessment o f the study? Yes-1 No-0
Are the results o f the study generalisable? Yes-1 No-0
Does this study help to answer your key question? Yes-1 No-0
Is there a statement o f funding? Yes-1 No-0
TOTAL SCORE (max 26)
Grading (A-D):
A = 70-100%;
B = 60-70% (Where criteria have not been fulfilled they are thought very unlikely to alter the 
reliability and validity of study findings).
C = 50-60% (Those criteria that have not been fulfilled or not adequately described are 
thought unlikely to alter the study findings)
D = 0-49% (The findings of the study are thought likely or very likely to be affected by study 
quality);
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Course Handbook Guidelines for Submission - Major research Project Proposal
The Major research Project Proposal should include the following headings:
• Full title of project
• Summary of Project
• Introduction
• Aims and Hypotheses
i. Aims
ii. Hypotheses
• Plan of Investigation
i. Participants
ii. Recruitment
iii. Measures
iv. Design and Procedures
V . Settings and Equipment
vi. Power Calculation
vii. Data Analysis
• Practical Applications
• Ethical Approval
• Timescale
• References
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Appendix 4.1 Guidelines for Submitting to Pain
GUIDELINES FOR SUBMITTING TO PAIN
1. General
Submission of a paper to PAIN is understood to imply that it has not previously been 
published (except in abstract form) and that it is not being considered for publication 
elsewhere. Manuscripts submitted under multiple authorship are reviewed on the assumption 
that
(1) all authors listed concur with the submitted version of the manuscript and with the 
listing of the authors;
(2) authorship credit is based on important contributions in one or more of the following 
areas: conception and design, analysis and interpretation of data, drafting of the 
manuscript or making intellectual contributions to its content;
(3) the final manuscript has been tacitly or explicitly approved by the responsible 
authorities in the laboratory or institution where the work was carried out.
If illustrations or other small parts of articles or books already published elsewhere are used in 
papers submitted to PAIN the written permission of author and publisher concerned must be 
included with the manuscript. The original source must be indicated in the legend of the 
illustration in these cases. The letter accompanying the manuscript should include a statement 
of any financial or other relationships that might lead to a conflict of interest, the 
recommended Section Editor to which the manuscript should be assigned to, and the names of 
four potential reviewers with complete contact details. The Publisher and Editors-in-Chief 
regret that they are unable to return copies of submitted manuscripts.
Articles should be written in English and should be complete in all respects. The layout and 
style should adhere strictly to the instructions given under ‘Organisation of the Article’ and, 
in particular, the reference style of PAIN. No revisions or updates will be incorporated after 
the article has been accepted and sent to the Publisher (unless approved by the Editors). For 
all types of papers the preferred method of submission is electronic via the WWW using the 
SMART Works website http://www.smartworks2Q00.com/smart20Q0/start/start.asn. 
However, if you are having difficulty with the on-line submission, please contact Pain at: 
tinay@iasp-pain.org. If you are not able to make e-mail contact, you may send one hardcopy 
of the manuscript, inculding copies of all illustrations, accompanied by a disk containing files 
of all the text and illustrations, to the attention of the Editor-in-Chief at the Editorial Office.
2. Preparing electronic manuscripts
Keep text and graphics (and any other items) as separate files — do not import the figures into 
the text file. Name your files using the correct extension, e.g. text.doc, figla.eps, figl.tif, 
Figl.cdr, tbl_16.xls, etc. Text files should be supplied in one of the following formats: 
Microsoft Word or WordPerfect, Windows or Macintosh formatted. The native format is 
preferred over ASCII text or Rich Text Format (RTF). Ensure that the letter "1" and the digit 
"1" (also letter "O" and digit "0") have been used properly, and format your article (tabs, 
indents, etc.) consistently. Characters not available on your word processor (Greek letters, 
mathematical symbols, etc.) should not be left open, but indicated by a unique code (e.g. 
gralpha, @, #, etc. for the Greek letter alpha). Such codes should be used consistently 
throughout the entire text. Please make a list of such codes and provide a key. When accepted 
articles are processed, most formatting codes will be removed or replaced so there is no need 
for you to use excessive layout styling. In addition, do not use options such as automatic word 
breaking, justified layout, double columns or automatic paragraph numbering (especially for 
numbered references). However, do use bold face, italic, subscripts, superscripts etc. for
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scientific nomenclature. When preparing tables, if you are using a table grid, please use only 
one grid for each separate table and not a grid for each row. If no grid is being used, use tabs 
to align columns, not spaces. Graphic files: See Elsevier Science’s website for guidelines for 
preparing electronic artwork: http://www.authors.elsevier.com/artwork The following are 
preferred formats: native formats of Adobe Photoshop and Adobe Illustrator. If this is not 
possible, the graphic files may also be supplied in either TIFF, JPEG or GIF format (with 
SMARTWorks submissions). All type fonts used in studio-created artwork must be either 
"embedded" in the file or supplied separately. All graphic files supplied as bitmap format (not 
vector format) in native Adobew Photoshop, TIFF, JPEG or GIF must be submitted in 
sufficiently high resolution (240-300 dpi for greyscale or colour images and 600-1000 dpi for 
line art) to allow for printing.
3. Submission of manuscripts
Electronic submission of articles via the Web using SMARTWorks. SMARTWorks is an 
integrated set of programs that facilitates the rapid submission and peer-review of manuscripts 
via the World Wide Web. SMARTWorks is at the core of SMARTPublication, the first fully 
integrated web-based publishing solution. It uses the WWW and the Internet to connect all 
users: authors, editorial staff, reviewers, and publisher. Advantages are greatly reduced time- 
to-review, time-to-publish, and time-to-read periods. When submitting a manuscript through 
SMARTWorks, full instructions for uploading data and files etc. are given on the 
SMARTWorks website: http://www.smartworks2QQQ.com/smart2000/start/start.asp Please be 
sure to include the version and computer platform when uploading the files. Electronic 
submission via SMARTWorks requires at least one original word processing file; if there are 
any associated data files (figures, etc.), these are to be included separately. It is the 
responsibility of the authors to create the proper files as instructed above for the electronically 
submitted manuscript. The editorial office cannot make conversions beyond the supported file 
types. No hardcopy manuscripts or illustrations are to be sent to the Editors unless specifically 
requested. Upon ‘notification of acceptance’ or ‘acceptance with minor revision’, two sets of 
hardcopy illustrations should be sent to the Editorial Office, for the purpose of checking the 
quality of the processed electronic files.
4. Submission of manuscripts
Manuscripts originally submitted as hardcopy: Provide the final form of the accepted article 
on an electronic storage medium (floppy-disk, ZIP/JAZ disk, or CD ROM). Save text and 
graphics files on separate disks. Label all disks with your name, journal to be published in, 
and file names. Please also include details of the word-processing software, compression 
software, and platform (PC, Mac, UNIX etc) used in the creation of your files. N.B. A 
hardcopy of both text and illustrations is also required -  it is essential that these are identical 
to the electronic files supplied.
5. Organization of the article
The manuscript should be in English, typed with double spacing with at least 4 cm margin on 
pages of uniform size. They should include a brief summary on a separate page, and should be 
in the usual form: Introduction, Methods, Results, Discussion, Acknowledgements, Reference 
List; not more than 6 keywords.
Title page.
The title page should contain the following items: (i) complete title (preferably no chemical 
formulas or arbitrary abbreviations); (ii) full names of all authors; (iii) complete affiliations of 
all authors; (iv) the number of text pages of the whole manuscript (including figures and 
tables) and the number of figures and tables; (v) the name and complete address of the 
corresponding author (as well as telephone number, facsimile number and E-mail address, and
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if available URL address) to whom correspondence and proofs should be sent; (vi) 
acknowledgements.
Literature references.
Citation of literature references in the text should be included in parentheses and should be by 
author(s) and year in chronological not alphabetical order. When papers written by more than 
two authors are cited in the text, the abbreviation ‘et al.’ should be used following the name of 
the leading author, even if the subsequent authors are not the same in all references. All 
references cited in the text must be listed at the end of the paper, should be typed double­
spaced, and arranged alphabetically by author. References must be complete, including 
initial(s) of author(s) cited, title of paper referred to, journal, year of publication, volume and 
page numbers. If more than two references with the same year and author(s) are cited, use 
lowercase letters after the year (Cousins 1982a,b; Melzack et al. 1984a,b). Journal titles 
should be abbreviated according to Index Medicus, List of Journals Indexed, latest edition. 
For citations of books, the following uniform sequence should be maintained: author(s), title 
of article, editor(s), complete title of book, place of publication, publisher, year and page 
numbers. Manuscripts in preparation and submitted but not accepted as well as ‘personal 
communications’ should not appear in the reference list but should be cited at the appropriate 
place in the text.
Examples:
Adams CWM. Neurohistochemistry. Amsterdam: Elsevier, 1965.
Goldenberg DL. Psychiatric and psychological aspects of fibromyalgia syndrome. Rheum Dis 
ClinN Am 1989a; 15:105-115.
Goldenberg DL. Fibromyalgia and its relation to chronic fatigue syndrome, viral illness and 
immune abnormalities. J Rheumatol 1989b; 16:91-93.
Turner JA. Coping and chronic pain. In: Bond MR, Charlton JE, Woolf CJ, editors. Pain 
research and clinical management. Proc. Vlth World Congress on Pain, Vol. 4. Amsterdam: 
Elsevier, 1991., pp. 219-227.
URLs should be included for all references that are publicly accessible via the Internet. 
Illustrations.
Authors should consult Elsevier Science’s website for guidelines for preparing (electronic) 
artwork: http://www.authors.elsevier.com/artwork It should be borne in mind that in the 
journal illustrations will appear either across a single column (=8.4 cm) or a whole page 
(=17.6 cm). The illustrations should be numbered in Arabic numerals according to the 
sequence of appearance in the text, where they are referred to as Fig. 1, Fig. 2, etc. Accepted 
manuscripts submitted on diskette that include electronic files of the illustrations must be 
accompanied by a hardcopy set of the final illustrations. All hardcopy illustrations should bear 
the author’s name, the orientation (top, bottom, etc.) and be numbered. Hardcopy colour 
figures should be submitted as separate prints and not be mounted on cardboard. Slides taken 
from labelled prints are also acceptable. Colour reproduction. Reproduction in colour will 
have to be approved by the Editor. Authors will be required to pay a fee towards the extra 
costs incurred in colour reproduction. The charges are E300.00 (approx. US $300) for the first 
page involving colour, and E200.00 (approx. US $200) per page for all subsequent pages 
involving colour in a given article (all prices include sales tax).
Figure legends.
Each illustration must have a title and an explanatory legend. The title should be part of the 
legend and not be reproduced on the figure itself. The legends should be numbered 
consecutively in Arabic numerals and should be placed on a separate page at the end of the
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manuscript and begin with the number of the illustration they refer to. All symbols and 
abbreviations used in the figure must be explained.
Tables.
Tables should be so constructed that they, together with their captions and legends, will be 
intelligible with minimal reference to the text. Tables of numerical data should each be typed 
(with double-spacing) on a separate page, numbered in sequence in Arabic numerals (Table 1, 
2, etc.), provided with a heading, and referred to in the text as Table 1, Table 2, etc. A detailed 
description of its contents and footnotes should be given below the body of the table.
Acknowledgements.
Acknowledgements should be placed at the end of the text before the Reference List and 
should specify: (1) contributions that need acknowledging but do not justify authorship; (2) 
acknowledgements of technical help; (3) acknowledgements of financial and material support, 
specifying the nature of the support; (4) financial arrangements that may represent a possible 
conflict of interest.
Policy issues.
Ethics of animal experiments. Authors will be required to show that they have paid attention 
to the proposals of the Committee for Research and Ethical Issues of IASP published in PAIN 
16 (1983) 109-110. Authors should indicate if the experimental work was reviewed by an 
institutional animal care and use committee or its equivalent.
Ethics of human experiments. Authors reporting on experimental work on humans should, 
where relevant, submit evidence that the work has been approved by an institutional clinical 
research panel or its equivalent.
Further information may be obtained from the Publisher, Elsevier Science Ireland Ltd., 
Elsevier House, Brookvale Plaza, East Park, Shannon, Co. Clare,
Ireland. Tel.: +353 61 709688; fax: +353 61 709110; email: p.flynn@elsevier.com
Proofs.
Authors should keep a copy of their manuscripts, as page proofs will be sent to them without 
the manuscript. In order to avoid a delay in publication, authors are requested to please return 
proofs within 48 hours by fax or express mail.
Page Charges.
There will be no page charges for PAIN.
Reprints.
A total of 50 reprints of each paper will be provided free of charge to the corresponding 
author. Additional copies can be ordered at prices shown on the offprint order form, which 
will be sent to the author upon receipt of the accepted article at the Publisher.
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Appendix 4.2 Study Invitation Letter and Patient Information Sheet
Invitation Letter (25/07/05)
Dear Sir/Madam,
Re: Chronic pain patient’s views on their illness and medication and how that 
affects the way they take their medication.
The pain clinic is conducting a research study over the next three months. This study will 
look at the views people with chronic pain have about their illness and medication and how 
these views affect the way they take their medication.
All patients who are due to attend the pain clinic are being sent this invitation letter and 
information sheet. However, not all patients attending the clinic will be selected to take part.
You may be invited to take part in the study when you attend your clinic appointment. In 
order for you to decide whether you wish to take part it is important for you to understand 
why the research is being done and what it will involve.
Please take the time to read the attached information sheet (Version3, 25/07/05) carefully and 
discuss it with others if you wish. You may ask the consultant at the clinic questions if you 
wish any further information or call the contact at the end of the information sheet.
Thank you for taking the time to consider the study.
Yours faithfully,
Leeanne Ramsay
Principal Investigator
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Patient Information Sheet
Version 3 (25/07/05)
Study Title:
Chronic pain patients’ views on their illness and medication and how that affects 
the way they take their medication.
Thank you for taking the time to read this information.
What is the purpose of the study?
This study will explore the views people with chronic pain have about their illness and the 
views they have about their medication. It will look at whether views about illness and 
medication affect the way people take their medication.
It is hoped that through understanding the way people think about their illness and medication 
we can improve the service provided to people suffering from chronic pain.
Why have I been asked to take part?
We are sending this information sheet to all people who are attending the Pain Clinic in the 
coming months, however not everyone attending the clinic will be asked to take part in the 
study. We are hoping to have 250 people take part in this study.
What do I have to do if I take part?
You may be given a study questionnaire pack at your clinic appointment. It is your choice to 
decide whether you would like to take part. The pack contains four brief questionnaires that 
you can fill in before you leave the clinic or complete at home and post back to us. This 
should take no longer than 30 minutes. The questionnaires will ask questions about your 
chronic pain, your views on medication and how you take your medication.
Do I have to take part?
No, you do not have to take part and you are free to change your mind and withdraw from the 
study at any time. Your decision to take part or not will not affect the standard of care you 
receive.
What are the possible benefits of taking part?
There is a growing recognition that the care people receive is improved when we understand 
people’s views about their medical condition and its treatment. It is hoped that the results of 
this study will improve the care people with chronic pain receive in the future.
What are the possible disadvantages of taking part?
We don’t anticipate there being any disadvantages to taking part. It is unlikely that you will 
find answering the questionnaires upsetting, however if you do feel you need to discuss any of 
the issues raised by the questionnaire you may contact Dr Dunbar, a Clinical Psychologist
150
attached to the Chronic Pain Service. His contact number is 0141-201-3005. Remember you 
are free to withdraw from the study at any time if you decide you no longer wish to take part.
If you have any complaints about the way you were approached about this study or treated 
during the study then you can complain through the normal NHS complaints process.
What will happen to the results of the study?
The research will be completed as part of a Doctorate in Clinical Psychology and the results 
will be available from the library at the University of Glasgow. It is also aimed that the 
results will be published in an appropriate scientific journal. If you would like a copy of the 
results once the study is finished you can contact the principal investigator at the address 
below.
Who will know what I have said?
If you decide to take part in the study your responses will be completely anonymous and no 
personal or identifying information will be available to anyone. This means that no action 
will be taken as a result of the answers given on your questionnaires.
Who is organising the funding for the study?
The study is being funded by the University of Glasgow.
Who has reviewed the study?
The study has been reviewed by the Ethics Committee at Greater Glasgow NHS primary care 
division and at Gartnavel General, Royal Infirmary and Stobhill hospitals.
Contact for further information:
Leeanne Ramsay (Principal Investigator)
Trainee Clinical Psychologist 
Department of Psychological Medicine 
Gartnavel Royal Hospital 
Glasgow, G12 OXH 
Telephone: 0141 211 0607
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Appendix 4.3 Ethics Approval Letters
Miss Leanne Ramsay
Trainee Clinical Psychologist
University of Glasgow
Department of Psychological Medicine
Gartnaval General Hospital
Glasgow
G12 0XH
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 OXH 
Tel: 0141 211 3600 
www.nhsgg.org.uk
NHS
Greater
Glasgow
Date 
Your Ref 
Our Ref
Direct line
Fax
E-mail
16 August 2005
0141 211 3824 
0141 211 3814 
anne.mcmahon@qartnavel. 
glacomen.scot.nhs.uk
Dear Miss Ramsay
Full title of study: The Role of Illness Perceptions and Treatment Beliefs in
Explaining Adherence to Pharmacological Treatment of 
Chronic Pain 
REC reference number: 05/S0701/51
Thank you for your letter of 25 July 2005, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.
The further information was considered at the meeting of the Committee held on 11 August 
2005. A list of the members who were present at the meeting is attached.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised.
The favourable opinion applies to the research sites listed on the attached form.
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully.
Approved docum ents
The final list of documents reviewed and approved by the Committee is as follows:
Document Version Date
Application 22 April 2005
Investigator CV Supervisor
CV
22 April 2005
Investigator CV 22 April 2005
Protocol 22 April 2005
Covering Letter 25 April 2005
Letter from Sponsor 22 April 2005
Compensation Arrangements Indemnity 22 April 2005
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Arrangemen
ts
Interview Schedules/Topic Guides 22 April 2005
Copy of Questionnaire ' 22 April 2005
Letters of Invitation to Participants 22 April 2005
Letters of Invitation to Participants twO 20 May 2005
Participant Information Sheet two 20 May 2005
Participant Information Sheet three 25 July 2005
Participant Information Sheet 22 April 2005
Participant Consent Form ' 22 April 2005
Response to Request for Further Information two 25 July 2005
Response to Request for Further Information one 14 June 2005
Management approval
The study should not commence at any NHS site until the focal Principal Investigator has 
obtained final management approval from the R&D Department for the relevant NHS care 
organisation.
Membership of the Committee
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.
Notification of other bodies
The Committee Administrator will notify the research sponsor that the study has a 
favourable ethical opinion.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
05/S0701/51   Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project,
Yours sincerely
A W McMahon
Research Ethics Co-ordinator (Manager) on behalf of Dr Paul Fleming. Chair
Email: Anne.McMahon@gartnavel.glacomen.scot.nhs.uk
Cc Attendance at Committee meeting on 11 August 2005 
Standard approval conditions 
Site approval form (SF1)
Primary Care Division
Gartnavel Royal Hospital 
1055 Great Western Road
Glasgow G12 OXH 
Tel: 0141 211 3600 
www.nhsgg.org.uk
Greater
Glasgow
Miss Leanne Ramsay
Trainee Clinical Psychologist
University of Glasgow
Department of Psychological Medicine
Gartnaval General Hospital
Glasgow
G12 0XH
Date 07 September 2005
Your Ref 
Our Ref
Direct line 0141 211 3824 
Fax 01412113814
E-mail anne.mcmahon@qartnavel.
glacomen.scot.nhs.uk
Dear Miss Ramsay
Full title of study: The Role of Illness Perceptions and Treatment Beliefs in
Explaining Adherence to Pharmacological Treatment of 
Chronic Pain 
REC reference number: 05/S0701/51
The REC gave a favourable ethical opinion to this study on 11 August 2005.
Further notification(s) have been received from local site assessor(s) following site-specific 
assessm ent. On behalf of the Committee, I am pleased to confirm the extension of the 
favourable opinion to the new site(s). I attach an updated version of the site approval form,
1 listing all sites with a favourable ethical opinion to conduct the research.
Management approval
The Chief Investigator or sponsor should inform the local Principal Investigator at each site of 
the favourable opinion by sending a copy of this letter and the attached form. The research 
should not commence at any NHS site until management approval from the relevant NHS 
care organisation has been confirmed.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
i 05/S0701/51_______________Please quote this number on all correspondence
Yours sincerely
Mrs Anne W McMahon
Research Ethics Committee Co-ordinator
154
D161181
Primary Care Division
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 OXH 
Tel: 0141 211 3600 
www.nhsgg.org.uk
NHS
Greater
Glasgow
Miss Leanne Ramsay
Trainee Clinical Psychologist
University of Glasgow
Department of Psychological Medicine
Gartnaval General Hospital
Glasgow
G12 0XH
Date 
Your Ref 
Our Ref
Direct line
Fax
E-mail
18 January 2006
0141 211 3824 
0141 211 3814 
anne.mcmahon@qartnavel. 
glacomen.scot.nhs.uk
Dear Miss Ramsay
FuSS titie of study: The Rc!s of liincss Perceptions and Treatm ent Beliefs in
Explaining A dherence to Pharm acological Treatm ent of 
Chronic Pain 
REC reference number: 05/S0701/51
Thank you for the amendment regarding the above named submission in which you indicate 
the alteration to the upper age limit.
The members of the Committee present gave a favourable ethical opinion of the amendment 
on the basis described in the notice of amendment form and supporting documentation.
M embership of the Committee
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.
R esearch governance approval
All investigators and research collaborators in the NHS should notify the R&D Department for 
the relevant NHS care organisation of this amendment and check whether it affects research 
governance approval of the research.
Statem ent of com pliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
[REC reference number]: 05/S0701^j Please quote this number on all correspondence
Yours sincerely
A W McMahon
R esearch Ethics Co-ordinator (Manager) on behalf of Dr Paul Fleming. Chair 155
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Appendix 1.4 Questionnaire Pack
UNIV ERSITY
GLASGOW
CH R O N IC  P A IN  P A T IE N T ’ S V IEW S ON T H E IR  ILLNESS 
AND M E D IC A T IO N  AND H O W  T H A T  AFFECTS TH E W A Y  
T H E Y  T A K E  T H E IR  M E D IC A T IO N
Thank you for agreeing to take part in this study. Please answer the 
following questions carefully and please try to answer A LL  the questions.
When you are finished please place your pack in the box marked pain 
questionnaires in the waiting room.
If you would like more time you may take the pack home and post it back to us at the 
following address:
Leeanne Ramsay (Principal Investigator)
Trainee Clinical Psychologist 
Department of Psychological Medicine 
Gartnavel Royal Hospital 
1055 Great W estern Road 
Glasgow, G12 OXH
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ABOUT YOU
1) W hat is your age: D D
(Please write your answer in the boxes provided.)
2) Are you:
(Please tick box.)
3) Please tell us a bit about your education:
(Please tick all boxes that apply.)
Left school before standard grade or equivalent D
Standard grade or equivalent D  SCOTVEC certificate D
Access course after leaving school D  HNC or HND
First or higher degree D Other D
4) W here do you have pain? (e.g. lower back, neck, legs)
5) How long have you had your pain condition?
Please indicate number of: years □ □  months □ □
6) How would you rate the pain you’ve had in the last 
week?
(please circle the appropriate number)
None Pain as bad as it could be
0 1 2 3 4 5 6 7 8 9  10
male D  female 0
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ABOUT YOUR MEDICATION
W e would like to know a little about the medication that 
you are currently prescribed for your pa in. 
Don’t worry if you can’t remember all details just fill in 
what you can.
7) How m an y  ty p e s  o f m ed ica tio n  do  you cu rre n tly  ta k e  fo r y o u r 
p a in ?  (Please write in box provided.) [H
8) P le a se  tell u s  a b o u t y o u r pain  m ed ica tio n  by c o m p le tin g  th e  tab le  
below .
Name of Pain Medication
How many times do you take 
it a day?
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QUESTIONS ABOUT USING YOUR MEDICINES
• W e would like to ask you a few questions about how you 
use your medicines.
• Many people find a way of using their medicines that suits 
them.
• This may differ from the label or from what the doctor has 
said.
• Here are some ways that people have said they use their 
medicines.
• For each of the statements please tick the box which best 
applies to you.
Your own w ay of 
using your 
m edicines
Always Often Sometim es Rarely Never
1 forget to take 
them
1 alter the dose
1 stop taking them 
for a while
1 decide to miss a 
dose
1 take less than 
instructed
1 take more than 
instructed
© R Horne
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YOUR VIEWS ABOUT MEDICINES PRESCRIBED FOR YOUR
CHRONIC PAIN
• We would like to ask about your personal views about 
medications prescribed for your chronic pain. Below are 
statements other people have made about their medicine.
• Please indicate the extent to which you agree or disagree 
with them by ticking the appropriate box. There are no 
right or wrong answers. We are interested in your 
personal views.
Views about your 
pain medication
Strongly
Agree
Agree Uncertain Disagree Strongly
Disagree
My health, at 
present, depends on 
my pain medications
Having to take pain 
medicine worries me
My life would be 
impossible without 
my pain medicines
Without my pain 
medicine 1 would be 
very ill
1 sometimes worry 
about the long-term 
effects of my pain 
medicines
My pain medicines 
are a mystery to me
My health, in the 
future, depends on 
my pain medicines
My pain medicines 
disrupt my life
1 sometimes worry 
about being too 
dependent on my 
pain medicines
My pain medicines 
protect me from 
becoming worse
© R Horne
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YOUR VIEWS ABOUT YOUR CHRONIC PAIN SYMPTOMS
• Listed below are a number of symptoms that you may or 
may not have experienced since your chronic pain.
• Please indicated by circling Yes or No, whether you have 
experienced any of these symptoms since your chronic 
pain, and whether you believe that these symptoms are 
related to your chronic pain (CP).
1 have experienced  
this since my CP
This symptom is 
related to my CP
Pain Yes No Yes No
Sore Throat Yes No Yes No
Nausea Yes No Yes No
Breathlessness Yes No Yes No
Weight Loss Yes No Yes No
Fatigue Yes No Yes No
Stiff Joints Yes No Yes No
Sore Eyes Yes No Yes No
Wheeziness Yes No Yes No
Headaches Yes No Yes No
Upset Stomach Yes No Yes No
Sleep Difficulty Yes No Yes No
Dizziness Yes No Yes No
Loss of Strength Yes No Yes No
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YOUR VIEWS ABOUT YOUR CHRONIC PAIN
• We are interested in your personal views of how you see 
your current chronic pain (CP).
• Please indicate how much you agree or disagree with the 
following statements about your chronic pain by ticking 
the appropriate box.
V iew s a b o u t y o u r  C P
Strongly
Agree
Agree Uncertain Disagree Strongly
Disagree
My CP will last a short time
My CP is likely to be 
permanent rather than 
temporary
My CP will last a long time
This CP will pass quickly
1 expect to have this CP for 
the rest of my life
My CP is a serious 
condition
My CP has major 
consequences on my life
My CP does not have much 
effect on my life
My CP strongly affects the 
way others see  me
My CP has serious 
financial consequences
My CP causes difficulties 
for those who are close to 
me
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Views about your CP (cont.)
Strongly
Agree
Agree Uncertain Disagree Strongly
Disagree
There is a lot 1 can do to 
control my symptoms
What 1 do can determine 
whether my CP gets better 
or worse
The course of my CP 
depends on me
Nothing 1 do will affect my 
CP
1 have the power to 
influence my CP
My actions will have no 
effect on the outcome of 
my CP
My CP will improve in time
There is very little that can 
be done to improve my CP
My treatment will be 
effective in curing my CP
The negative effects of my 
CP can be prevented 
(avoided) by my treatment
My treatment can control 
my CP
There is nothing which can 
control my condition
The symptoms of my 
condition are puzzling to 
me
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Views about your CP 
(cont.)
Strongly
Agree
Agree Uncertain Disagree Strongly
Disagree
My CP is a mystery to me
1 don’t understand my CP
My CP doesn’t make sen se  
to me
1 have a clear picture or 
understanding of my 
condition
The symptoms of my CP 
change a great deal from 
day to day
My symptoms come and 
go in cycles
My CP is very 
unpredictable
1 go through cycles in 
which my CP gets better 
and worse
1 get depressed when 1 
think about my CP
When 1 think about my CP 1 
get upset
My CP makes me feel 
angry
My CP does not worry me
Having this CP makes me 
anxious
My CP makes me feel 
afraid
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CAUSES OF YOUR CHRONIC PAIN
• We are interested in what you consider to be the cause of 
your chronic pain.
• As people are very different, there is no correct answer to 
this question.
• We are most interested in your own views about the 
factors that caused your chronic pain rather than what the 
doctors or fam ily may have suggested to you.
• Below is a list of possible causes for your chronic pain.
• Please indicate how much you agree or disagree that they 
were causes for your chronic pain by ticking the 
appropriate box.
Possible Causes
Strongly
Agree
Agree
Neither 
Agree Nor 
Disagree
Disagree
Strongly
Disagree
Stress or W orry
Hereditary -  it runs 
in the family
A germ or virus
Diet or eating habits
Chance or bad luck
Poor medical care  
in my past
Pollution in the 
environm ent
My own behaviour
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Possible Causes 
(cont.)
Strongly
Agree
Agree
Neither 
Agree Nor 
Disagree
Disagree
Strongly
Disagree
My mental attitude 
i.e. thinking about 
life negatively
Family problems or 
worries
Overwork
My emotional state 
e.g. feeling down, 
lonely, anxious
Aging
Alcohol
Smoking
Accident or injury
My personality
Altered immunity
Please rank order the three most important factors that you now 
believe caused your chronic pain. You may use the items from the 
box above, or you may have additional ideas of your own.
The most im portant causes for me are:
1 ) _____________________________________
2 ) _____________________________________________
3 ) ___________________________________
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THANK YOU VERY MUCH FOR 
COMPLETING THIS QUESTIONNAIRE.
Please could you look back to check that you haven’t 
missed any questions by mistake.
PLEASE PUT YOUR COMPLETED QUESTIONNAIRE IN 
THE BOX PROVIDED IN THE CLINIC.
YOU CAN ALSO CHOOSE TO POST THIS QUESTIONNAIRE BACK TO ME 
AT THE ADDRESS PROVIDED ON THE FRONT PAGE.
Questionnaire Pack Version 2 (20/05/05)
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Appendix 4.5 Calculating ‘goodness of fit’ in Structural Equation Modelling
Calculating ‘goodness of fit’ in Structural Equation Modelling (SEM)
Models can be tested for ‘goodness o f fit’ using a number o f different criteria. It is 
possible to use just a chi-square statistic (x ) but it is recommended that a range of
statistics be used to evaluate model fit (Bentler, 1995). This is because o f limitations
. . 2 with individual indices e.g. % is rarely non-significant.
The following three criteria were adopted to assess goodness o f fit in this study:
1) The chi-square statistic (x ) is a measure o f whether the residual correlations 
obtained by comparing the observed and predicted values differ from 0. If the 
X  is small in reference to the degrees of freedom the statistic is not significant 
and the model is considered to be a plausible representation o f the causal
* i  i • • •  2 .processes in the underlying data. However it is recommended that the x is not 
the sole measure o f model fit because it is affected by sample size e.g. larger 
samples produce larger chi-squares that are more likely to be significant (Type 
I error), as well as model size and distribution o f variables.
2) The second criterion is the confirmatory fit index (CFI), which is a measure of 
the fit between the theorized model and the data. This index can assume a 
value between 0 and 1, and is independent of sample size and relatively robust 
against departures from normality. The index is closer to one when the model 
fits closely with the data.
3) The third criterion takes into account the population error o f approximation 
(expressed as the root-mean-square error o f approximation, RMSEA), which is 
a measure o f the degree to which the model holds in larger samples (i.e., is a 
measure o f generalisability). Values up to 0.05 indicate a close fit in larger 
populations, and values up to 0.08 represent reasonable errors of 
approximation in smaller populations.
Hu and Bentler (1999) empirically examined various cutoffs for measures in SEM, 
and their data suggest that to minimize Type I and Type II errors under different 
conditions, one should use a combination of a relative fit index i.e. CFI and the
• r> 2RMSEA (good models < .06). Therefore, the model was said to fit the data il the j f  
statistic was not significant (p= >0.05), the adjusted goodness-of-fit index (CFI) was 
high (preferably > 0.90) and the RMSEA was 0.05-0.08.
A model may be respecified and the fit o f the revised model evaluated (Kline, 1998). 
The specification should be guided by the researcher's hypothesis.
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